Open access peer-reviewed chapter

Helicobacter pylori and Hematologic Diseases

Written By

Germán Campuzano-Maya

Submitted: May 21st, 2015 Reviewed: March 9th, 2016 Published: July 7th, 2016

DOI: 10.5772/62971

Chapter metrics overview

1,541 Chapter Downloads

View Full Metrics

Abstract

Helicobacter pylori infection is the most common infection of the human species, with developing countries displaying a marked disadvantage in contrast to developing countries. While H. pylori infection is asymptomatic in most infected individuals, it is intimately related to malignant diseases of the stomach, such as gastric cancer and gastric MALT lymphoma, as well as benign diseases, for example chronic gastritis and duodenal and gastric peptic ulcers. Since the discovery that gastric mucosa could be colonized by bacteria, evidence of greater than 50 extragastric manifestations has been reported, linking H. pylori infection and the development of diseases associated with cardiology, dermatology, endocrinology, obstetrics and gynecology, hematology, pneumology, neurology, odontology, ophthalmology, otorhinolaryngology, and pediatrics. This chapter presents the extragastric manifestations of H. pylori infection expressed through hematologic diseases; particularly those included in the international consensus, and discusses guidelines for the management of H. pylori infection, such as iron deficiency, vitamin B12 (cobalamin) deficiency, and immune thrombocytopenia. Other manifestations reviewed include immune neutropenia, antiphospholipid syndrome, and plasma cell dyscrasias, such us monoclonal gammopathy of undetermined significance, multiple myeloma, and Henoch–Schönlein purpura.

Keywords

  • Helicobacter pylori
  • iron deficiency
  • immune thrombocytopenia
  • mucosa-associated lymphoid tissue lymphoma
  • vitamin B12 deficiency

1. Introduction

Helicobacter pyloriinfects greater than 50% of the world population’s stomachs, therefore constituting the most common infection of the human species [1]. A marked disadvantage exists between developed countries, where the prevalence ranges between 30% and 50%, and developing countries, where the prevalence ranges between 80% and 90% [2]. Since the discovery in 1983 that the stomach could be colonized by bacteria [3], sufficient evidence has accumulated implicating H. pylorias a pathogen intimately related to benign stomach diseases, such us chronic gastritis and duodenal and gastric peptic ulcers [3], and malignant diseases, for example gastric cancer [4] and gastric MALT lymphoma [5]. Furthermore, during the last three decades following the discovery [3], approximately 50 extragastric diseases have been reported in medical specialties such as cardiology, dermatology, endocrinology, obstetrics and gynecology, pneumology, neurology, odontology, ophthalmology, otorhinolaryngology, pediatrics, and hematology [6-20], the last of which is the subject of this review.

From a practical standpoint, hematological associations with H. pyloriinfection can be arbitrarily divided into two groups: (1) hematological diseases with sufficient scientific evidence to be recognized by the consensus and guidelines for the management of H. pyloriamong the indications of study and eradication and (2) hematological diseases where there is suspicion, with greater or lesser scientific evidence, of an association with H. pyloriinfection. Table 1 presents the hematological diseases associated with or possibly associated with H. pyloriinfection.

Recognized manifestations
Iron deficiency
Vitamin B12 deficiency
Immune thrombocytopenia
Gastric MALT lymphoma
Unrecognized manifestations
Autoimmune neutropenia
Antiphospholipid syndrome
Plasma cell dyscrasias
Henoch–Schönlein purpura
Other manifestations: acute leukemia, myelodysplastic syndrome, thrombocytosis

Table 1.

Hematologic manifestations of H. pyloriinfection

Advertisement

2. Hematological diseases recognized as related to H. pylori

Until September 2015, the scientific community has recognized three hematologic diseases as extragastric manifestations of H. pyloriinfection: iron deficiency [21-30], vitamin B12 deficiency [27, 29], and immune thrombocytopenia (ITP) [21, 23-31]. These will be carefully analyzed in the following subsections. Gastric MALT lymphoma, although considered a disease in the oncohematologic field and is associated with H. pyloriinfection, is not presented in this review because it is recognized as gastric manifestation.

2.1. Iron deficiency

Iron deficiency, with or without anemia (anemia sine anemia), is a serious public health problem, which affects approximately 25% of the world’s population (greater than two billion people), according to the World Health Organization (WHO). Importantly, it mainly affects disadvantaged populations, such as children and women of gestational age [32, 33]. Iron deficiency, with or without anemia, is associated with increased morbidity due to high susceptibility to infections, decreased labor productivity, delayed weight–height and cognitive development, and other conditions [34].

It is important to note that iron deficiency is a chronic process: an iron imbalance can take several years to become established and manifest clinically or through hemogram (blood cell count) parameters, such as morphological alterations of erythrocytes or anemia, according to the WHO criteria [32]. Three stages of iron deficiency are clearly established: prelatent (Stage 1), when serum ferritin is between 12 µg/L and 30 µg/L; latent (Stage 2), when serum ferritin is below 12 µg/L; and iron deficiency anemia (Stage 3), when anemia is observed in addition to diminished or depleted iron storage levels determined by serum ferritin [35].

2.1.1. H. pyloriand iron deficiency

In 1991, in Belgium, Blecker et al. described the first association between iron deficiency and H. pyloriinfection. The patient was a 15-year-old young with iron deficiency anemia (hemoglobin 8.5 g/dL) secondary to chronic active hemorrhagic gastritis, positive to H. pylori, without prior gastrointestinal manifestations, in whom after H. pylorieradication the hematologic parameters and ferrokinetics test returned to normal without requiring supplemental iron treatment [36]. Two years later, in France, Bruel et al. reported a second case of iron deficiency anemia (hemoglobin 5.6 g/dL), in an 11-year-old child, which manifested as an upper gastrointestinal hemorrhage with documented infection with H. pylori. The anemia was resolved after eradication of the infection, again without supplemental iron treatment [37]. In the same year, in Italy, Dufour et al. presented the case of a 7-year-old boy diagnosed with refractory iron deficiency anemia (hemoglobin 5.1 g/dL), who had been treated with oral iron, the presence of H. pyloriwas reported and was asymptomatic from the viewpoint of gastrointestinal manifestations. As in the preceding cases, the infection was eradicated without supplementary iron treatment and the hematologic parameters, including hemoglobin (13.0 g/dL), returned to normal after 6 months [38].

After these first reports, where iron deficiency disappeared after the eradication of H. pylori[36-38], new isolated cases were published in last century [39-43], which as the first series demonstrate the association of H. pyloriwith iron deficiency and iron deficiency anemia [40, 44, 45]. The first decade of the twenty-first century provided most of the studies that currently support the five meta-analyses associating H. pyloriinfection with iron deficiency and the resolution of disease following infection eradication [46-50] in children [51-60], in pubescent males and females [61, 62], in prepubertal girls [63], in adult men and women [40, 45, 64-75], in seniors [76], in pregnant women [63], and in non-pregnant women [77]. In addition, these studies have provided scientific support to the different consensus and guidelines for incorporating iron deficiency into the medical management of H. pyloriinfection as an extragastric manifestation and indication for eradication [21-30].

2.1.2. Pathophysiology of iron deficiency by H. pylori

The pathophysiological mechanisms through which H. pyloriis associated with the etiology of iron deficiency, with or without anemia, has not been fully elucidated, and more questions remain than answers. Possible explanations proposed to clarify the association between H. pyloriand iron deficiency will be enunciated. However, it is not yet known why this association exists in some patients but not in others, where a different association is presented or the infection is asymptomatic, as happens in most cases [78].

In the past decade, H. pyloriinfection and iron deficiency have been linked through a recently discovered hormone called hepcidin [79]. Hepcidin is a hormone of hepatic origin that regulates iron absorption at the enterocyte level in the small intestine and the liberation of stored iron from the macrophages of reticuloendothelial system [80]. Hepcidin is elevated, as an acute phase reactant, in response to inflammation in the gastric mucosa. This in turn translates into a physiological iron deficiency, known clinically as anemia of chronic inflammation [81-85]. Preliminary studies show that serum hepcidina levels are elevated in patients infected with H. pylori[85-87] and return to normal after eradication of the infection [88], thereby permitting iron absorption in enterocytes and liberation from entrapment in the macrophage reticuloendothelial system.

Other possible causes of iron imbalance in patients infected with H. pylorican result from chronic gastritis, which occurs in all infected individuals [78]. This condition can generate bleeding when transforms into erosive gastritis [89], especially in patients with bleeding duodenal or gastric peptic ulcers [90, 91] and in patients who chronically consume non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, for the purpose of cardioprotection [92-95]. Other mechanisms invoked to explain iron deficiency in patients infected with H. pyloriare related to changes in gastric physiology, particularly changes in gastric pH and the presence of achlorhydria, which significantly reduces the solubility and intestinal absorption of inorganic iron [40].

Beyond the aforementioned evidence, certain highly virulent strains of H. pylori, such as those with cytotoxin-associated gene A (CagA) and vacuolating cytotoxin gene A (VacA), which act through molecular mimicry mechanisms, are more likely to develop or magnify iron deficiency in infected patients, compared with infected patients with strains not carrying these genes [71, 96-98]. This situation could explain, in part, the marked differences from one region to another and the large discrepancies observed in different studies.

2.1.3. Management of iron deficiency in the post-Helicobacterera

Regarding to the management of iron deficiency in the post-Helicobacterera, it is important to clarify that H. pyloriis not the only cause of iron deficiency, and its incorporation into the consensus and management guidelines of H. pylorias an indication to investigate and eradicate the infection is not a substitute for an adequate study of the most common causes of iron deficiency. These situations are particular to each region, according to prevalence of iron deficiency and H. pyloriinfection, which vary from place to place. Thanks to over 250 referenced studies in the literature aiming to clarify different aspects of the association between H. pyloriand the development of iron deficiency, five meta-analyses are now available that demonstrate the impact of infection on the development of iron deficiency and that infection eradication improves hematological parameters and ferrokinetics [46-50]. These analyses have enabled the scientific community, particularly the consensus and management guides, to incorporate iron deficiency of unexplained origin as an indication to evaluate and eradicate H. pyloriinfection, when present, in adults as well as children [21-30].

Before initiating treatment for a patient with iron deficiency, an assessment of the prevalence of H. pyloriinfection should be performed according to region. Generally, the prevalence is low in developed countries; these cases should proceed with conventional management of iron deficiency [32, 35]. In developing countries, the rate of H. pyloriinfection is high; in these cases or when the patient, despite living in a country where infection rates are low, comes from a country where the infection rates are high, it should proceed to determine the status of H. pylorithrough a non-invasive test, ideally the 13C-urea breath test [27]. If the patient is negative for H. pylori, it is necessary to investigate other causes of the iron deficiency and treat the patient conventionally [32, 35], whereas if the patient is positive for H. pylori, it is indispensable to eradicate the infection [27].

After 6–8 weeks of treatment, the infection eradication must be confirmed using a non-invasive test, ideally with 13C-urea breath test [27]. If eradication is not achieved, it is mandatory to establish a new therapy scheme until eradication is achieved. Once H. pylorieradication is achieved and an improvement in hematological parameters and ferrokinetics (complete or partial remission) is obtained, it is important to periodically evaluate the clinical hematological parameters and the indicators of iron levels. If there is no response, it must establish a conventional management of iron deficiency [32, 35].

Figure 1 shows a diagnostic and management algorithm of iron deficiency in the post-Helicobacterera, taking into account the prevalence of infection and H. pyloristatus.

Figure 1.

Algorithm for the study and management of iron deficiency, with or without anemia, in the post-Helicobacterera. (1) Before initiating treatment for a patient with iron deficiency, an assessment of the prevalence ofH. pyloriinfection should be performed in each region. Generally, it is high in developing countries and low in developed countries [1]. (2) If the rates ofH. pyloriinfection are low, proceed with a conventional management of iron deficiency [32,35]. (3) If the rates ofH. pyloriinfection are high or the patient, despite living in a country where infection rates are low, comes from a country where the infection rates are high, proceed to determine the status ofH. pylorithrough a non-invasive test, ideally the 13C-urea breath test (13C-BUT) [27]. (4) If the patient is negative forH. pylori, investigate other causes of the iron deficiency and treat conventionally [32,35]. (5) If the patient is positive forH. pylori, proceed with eradication of the infection [27]. (6) Confirm infection eradication 6–8 weeks after the treatment using a non-invasive test, ideally with the 13C-urea breath test [27]. (7) If eradication is not achieved, establish a new scheme of eradication therapy until it is achieved. (8) OnceH. pylorieradication is achieved, (9) if a response is obtained in the hematological parameters and ferrokinetics (complete or partial remission), periodically evaluate the clinical hematological parameters and indicators of iron. (10) If there is no response, proceed with a conventional management of iron deficiency [32,35].

2.2. Vitamin B12 deficiency

Vitamin B12, also known as cobalamin, is a coenzyme necessary for the metabolism of amino acids, such as methionine, threonine, and valine, and for DNA synthesis through the conversion of methyl-tetrahydrofolate to tetrahydrofolate [99]. Vitamin B12 is synthesized in mammals, but for humans, their provision depends exclusively of diet intake of animal products [99].

Again, as with iron deficiency, it should be noted that vitamin B12 deficiency is a chronic process, with very slow establishment. It may manifest clinically through neuropsychiatric symptoms or through hemogram parameters, such as morphological alterations of erythrocytes or anemia, according to the WHO criteria [32]. Four stages of vitamin B12 deficiency are clearly established: Stage I, reduction of vitamin B12 levels in blood; Stage II, low amount of vitamin B12 cellular levels and metabolic disorders; Stage III, increase in homocysteine and methylmalonic acid levels and decrease in DNA synthesis with onset of neuropsychiatric symptoms; and Stage IV, macrocytic anemia [100].

Vitamin B12 deficiency is defined in terms of the serum values of vitamin B12 and two components of its metabolic pathway, homocysteine and methylmalonic acid [101]. The diagnosis of vitamin B12 deficiency is established in accordance with the following criteria: (1) serum vitamin B12 < 150 pmol/L (< 200 pg/mL) with clinical manifestations and/or hematological alterations related to vitamin B12 deficiency; (2) serum vitamin B12 < 150 pmol/L, measured on two separate occasions; (3) serum vitamin B12 < 150 pmol/L and serum homocysteine > 13 mmol/L or urinary methylmalonic acid > 0.4 mmol/L (in the absence of renal failure, folic acid deficiency, and vitamin B6 deficiency); and (4) levels of serum holotranscobalamin < 35 pmol/L [102].

The prevalence of vitamin B12 deficiency is highly variable and represents a serious public health problem, depending on the populations analyzed. Epidemiologic studies show that, in the general population of industrialized countries, vitamin B12 deficiency has a prevalence of approximately 20%, with a range between 5% and 60%, depending on the definition of vitamin B12 deficiency that is utilized [101, 102]. The prevalence of vitamin B12 deficiency expressed as pernicious anemia is higher in Latin American countries than in the rest of the world; furthermore, in Latin America, the disease occurs in younger persons [103], while it is associated with advanced age in remaining countries [104].

In addition to its close association to the etiology of pernicious anemia [105] and subacute combined degeneration [106], vitamin B12 deficiency is related, through homocysteine, with dissimilar diseases such as Alzheimer’s disease [107, 108], dementia [109, 110], depression [111], stroke [112, 113], pulmonary embolism [114, 115], acute myocardial infarction, and coronary heart disease [116].

2.2.1. H. pyloriand vitamin B12 deficiency

The possibility that pernicious anemia, rather than vitamin B12 deficiency, was associated with H. pyloriwas the first extragastric association postulated within the scientific community. This postulation was made by O’Connor et al. in 1984 [117], a year after Warren and Marshall inform the scientific community that the stomach could be colonized by bacteria [3]. Despite this premature interest, the association has been difficult to sustain and, rather, has been denied by many authors. Fong and colleagues performed what is considered the first well-founded study to clarify the probable link between H. pyloriinfection and pernicious anemia. In this study, the authors concluded that patients that suffer pernicious anemia are protected against H. pyloriinfection and that the bacteria not invade the inflamed mucosa by isolated processes [118]. These data were ratified in a Japanese study made by Saito et al. [119] and have been shared by other authors, however, with the wrong conclusion [120].

It is currently known that when vitamin B12 deficiency becomes clinically relevant, the bacteria are no longer at the site of the lesion due to changes in the gastric mucosa that result in a hostile environmental niche. In cases of vitamin B12 deficiency and pernicious anemia, H. pyloridisappears as a result of changes mediated by the immunological response. These changes can be evidenced by the presence of antibodies against parietal cells and intrinsic factor after the bacteria have left the gastric mucosa [121, 122]. Moreover, H+/K+ ATPase autoantibodies, which are closely linked to classical autoimmune gastritis, are also important indicators of mucosal atrophy in H. pylorichronic gastritis [123]. H. pylorialso disappears from the gastric mucosa as a result of the histological and physiological changes induced by chronic atrophy in the case of gastric cancer [124].

Infection with H. pylorican also cause malabsorption of different micronutrients [125] like vitamin B12 [125-127]. A systematic review and meta-analysis of 17 studies with 2454 patients demonstrated a significant reduction in serum vitamin B12 levels in patients infected with H. pyloriwhen compared with uninfected persons [128]. Marino et al. demonstrated a correlation between the decrease in serum vitamin B12 levels and the increase in serum homocysteine due to H. pyloriinfection in 62 older patients: in these same patients, following infection eradication, an increase in serum vitamin B12 levels and a decrease in serum homocysteine levels occurred until normalization was reached [127].

The intimately association of pernicious anemia with the probability to develop stomach cancer was widely recognized by scientific community many years before the relationship between H. pyloriand stomach cancer was known [129-132]. Recently, Vanella et al. validated this association through a systematic review and meta-analysis, establishing that patients with pernicious anemia (vitamin B12 deficiency) have a relative risk of developing gastric cancer of 6.8 (95% CI: 2.6–18.1) [133].

2.2.2. Pathophysiology of vitamin B12 deficiency

The pathophysiological mechanism by which H. pyloriis related to the etiology of vitamin B12 deficiency has not been fully clarified, and many questions remain. Possible explanations aiming to clarify the association of H. pyloriwith vitamin B12 deficiency are described below. It is not yet known why this association occurs in some patients but not in others, where a different association is presented or the course of the infection is asymptomatic, as happens in most cases [78].

Vitamin B12 deficiency manifests as antibodies against intrinsic factor and the parietal cells in the stomach, achlorhydria, and decreased pepsinogen I and gastrin, thereby presenting an histological picture of chronic type A gastritis (autoimmune) [105]. The lack of intrinsic factor, which occurs as result of these changes in the gastric mucosa, reduces the absorption and transport of vitamin B12 that comes from the diet. Chronic atrophic gastritis, induced immunologically, evolves over a period of 10–30 years, until reaching gastric atrophy and the development of pernicious anemia, to the extent that the stores of vitamin B12 are depleted [105]. Vitamin B12 deficiency, parallel to the development of pernicious anemia, causes peripheral neuropathy and lesions in the posterior and lateral columns of the spinal cord, known as subacute combined degeneration, that progresses with demyelination and axial degeneration and eventually neural death [105].

2.2.3. Management of vitamin B12 deficiency in the post-Helicobacterera

Respect to the management of vitamin B12 deficiency in the post-Helicobacterera, it must be clarified that H. pyloriis not the only cause of vitamin B12 deficiency, and its incorporation into the consensus and management guidelines of H. pylorias an indication to investigate and eradicate the infection is not a substitute for an adequate study of the most common causes of vitamin B12 deficiency. These situations are particular to each region, according to the prevalence of vitamin B12 deficiency and H. pyloriinfection, which vary from place to place.

A recent systematic review and meta-analysis with the aim of clarifying the association between H. pyloriand the vitamin B12 deficiency evaluated the serum vitamin B12 levels from 17 studies involving a total of 2454 patients, infected or not with H. pylori. This study revealed that serum vitamin B12 levels are significantly lower in infected patients than in uninfected patients and that H. pylorieradication significantly increases vitamin B12 levels [128]. This has enabled the inclusion of vitamin B12 deficiency in the consensus and management guides of H. pyloriinfection as an indication to evaluate and eradicate the bacteria [27, 29].

Before initiating treatment for a patient with vitamin B12 deficiency, an assessment of the prevalence of H. pyloriinfection should be performed according to region. Generally, the prevalence is low in developed countries; in these cases should proceed with conventional management of vitamin B12 deficiency [134]. In developing countries, the rate of H. pyloriinfection is high; these cases or when the patient, despite living in a country where infection rates are low, comes from a country where the infection rates are high, it should proceed to determine the status of H. pylorithrough a non-invasive test, ideally the 13C-urea breath test [27]. If the patient is negative for H. pylori, it is necessary to investigate other causes of the vitamin B12 deficiency and treat the patient conventionally [134], whereas if the patient is positive for H. pylori, it is indispensable to eradicate the infection [27].

After 6–8 weeks of the treatment, the infection eradication must be confirmed using a non-invasive test, ideally with 13C-urea breath test [27]. If eradication is not achieved, it is mandatory to establish a new therapy scheme until eradication is achieved. Once H. pylorieradication is achieved and an improvement in hematological parameters and vitamin B12 levels (complete or partial remission) is obtained, it is important to evaluate them for a certain time. If there is no response, it must establish a conventional management of vitamin B12 deficiency [134].

Figure 2 shows a diagnostic and management algorithm of vitamin B12 deficiency in the post-Helicobacterera, taking into account the prevalence of the infection and H. pyloristatus.

Figure 2.

Algorithm for the study and management of vitamin B12 deficiency in the post-Helicobacterera. (1) Before initiating treatment for a patient with vitamin B12 deficiency, an assessment of the prevalence ofH. pyloriinfection should be performed in each region. Generally, prevalence is high in developing countries and low in developed countries [1]. (2) If the rates ofH. pyloriinfection are low, proceed with a conventional management of vitamin B12 deficiency [134]. (3) If the rates ofH. pyloriinfection are high or the patient, despite living in a country where infection rates are low, comes from a country where the infection rates are high, proceed to determine the status ofH. pylorithrough a non-invasive test, ideally the 13C-urea breath test (13C-BUT) [27]. (4) If the patient is negative forH. pylori, investigate other causes of vitamin B12 deficiency and treat conventionally [134]. (5) If the patient is positive forH. pylori, proceed with eradication of the infection [27]. (6) Confirm infection eradication 6–8 weeks after treatment using a non-invasive test, ideally the 13C-urea breath test [27]. (7) If eradication is not achieved, establish a new scheme of eradication therapy until it is achieved. (8) OnceH. pylorieradication is achieved, (9) if a response is obtained in the hematological parameters and the serum levels of vitamin B12 and homocysteine (complete or partial remission), periodically evaluate the clinical hematological parameters and indicators of vitamin B12. (10) If there is no response, proceed with a conventional management of vitamin B12 deficiency [134].

2.3. Immune thrombocytopenia (ITP)

ITP is the most frequent immunological disease in hematology [135]. The annual incidence of ITP is 5.5 per 100000 persons when the platelet count cut-off point is 100 × 109/L and 3.2 per 100000 persons when the platelet count cut-off point is 50 × 109/L [136]. The chronic form of ITP increases with age, being twice as high in people older than 60 years with respect to those younger than 60 years [136, 137], with a higher incidence in women (2:1) than in men (3:1) [138].

Primary ITP, formerly known as idiopathic thrombocytopenic purpura (ITP) and autoimmune thrombocytopenic purpura, has recently been redefined and adjusted in light of new knowledge represented in the Vicenza Consensus [139]. ITP was established as an autoimmune disorder characterized by isolated thrombocytopenia (peripheral blood platelet count below 100 × 109/L) in the absence of another possible causes or conditions related to thrombocytopenia [139]. Primary ITP diagnosis continues to be one of the exclusions due to current lack of robust clinical and laboratory parameters, with high accuracy to establish its diagnosis [139]. The main clinical concern of primary ITP is the elevated risk of bleeding; however, bleeding symptoms are not present all the time [139].

H. pyloriinfection is included as a new disease at the list of diseases potentially associated with the development of ITP; therefore, it must be ruled out in cases where thrombocytopenia by H. pyloriinfection is suspected [139], according to the establishment by the British Society for Haematology at beginning of 2003 [140]. In addition, the Vicenza Consensus conserved the acronym ITP to refer to the disease itself to avoid confusion and chose the term “primary immune thrombocytopenia” or “primary ITP” as a substitute name for ITP (idiopathic thrombocytopenic purpura) or autoimmune thrombocytopenic purpura, referring to cases where any associated causes are excluded. For cases where an underlying disease is present, it is recommended to use the term “secondary immune thrombocytopenia” or “secondary ITP,” followed by the name of the associated condition. For example, for the cases possibly initiated by H. pyloriinfection, it must be used with the extent “secondary ITP H. pylori–associated,” which required the demonstration of complete resolution of ITP after proving the eradication of the bacteria. This form in clinical practice could be called “ITP H. pylori–associated” [139].

2.3.1. H. pyloriand immune thrombocytopenia

The association of H. pyloriwith ITP was first reported by Garcia-Perez et al. in Spain in 1993; this report described a patient whose platelet count returned to normal values after eradication of H. pylori[141]. The medical literature subsequently reported similar cases in Japan [142-146], Italy [147-149], and Turkey [150].

In Italy, in 1998, Gasbarrini et al. presented the first series of cases demonstrating the association of H. pyloriwith adult ITP, reporting a recovery in platelet counts with disappearance of autoantibodies against platelets in six of eight ITP patients infected with H. pylori, after successful eradication of the bacteria [151]. Including this first series [151], 40 series have been described in the medical literature until now, and these reports consistently demonstrate the association between H. pyloriinfection and platelet count recovery following eradication. Ten of these series were reported in Europe: eight in Italy [151-158], one in Turkey [159], and one in Serbia [160], with a total of 495 ITP patients, 288 (58.2%) of whom were infected with H. pylori. Of these, 242 received eradication therapy. Successful eradication was achieved in 222 (91.7%) patients, and a platelet response was observed in 108 (48.6%) patients. Asian countries have provided 28 published series: 23 in Japan [161-183], two in China [184, 185], two in Iran [186, 187], and one in South Korea [188], with 1525 total ITP patients, 1089 (71.4%) of whom were infected with H. pylori. A total of 929 patients received eradication therapy, it was successful in 811 (87.3%) and 472 (58.2%) patients demonstrated a platelet response. In America, only two series have reported an association between H. pyloriand ITP: the first in Colombia [189] and the second in Canada [190]. The series in Colombia presented 32 patients with ITP, 29 (90.6%) of whom were infected with H. pylori. Those 29 patients received eradication therapy, and it was successful in 26 (89.7%) and 21 (80.8%) patients demonstrated a platelet response [189]. The association of H. pyloriinfection with ITP has not been reported in adults or children from Oceania or the continent of Africa.

A consolidated analysis of the 40 series reported worldwide reveals a total of 2074 patients with ITP, 1410 (68.0%) of whom are H. pylori-positive. A total of 1204 received eradication therapy, which succeeded in 1062 (88.2%); 604 (56.9%) of these patients demonstrated a platelet response. In general, Europe has a mean infection rate of 59.2% in patients with ITP and a mean platelet response in 48.6% of those patients; respective rates in Asia are 70.7% and 58.2%, and those in America (Colombia) are 90.6% and 80.8%. When consolidated, the 40 series exhibit a mean infection rate of 68.0% in patients with ITP, with a mean platelet response in 56.9% of those patients [191]. Table 2 summarizes the results of these series demonstrating an association between H. pyloriinfection and ITP development in adults and its response to H. pylorieradication [191]. Nevertheless, additional studies in Spain [192], France [193], the United States [193, 194], and Mexico [195] found no association between H. pyloriinfection and adult chronic ITP, explainable, at least in part, by the low prevalence of infection in these countries and insufficient samples.

ContinentNumber of
series
Number of patients with ITPNumber of H. pylori- infected ITP patients (%)Number of treated patientsNumber H. pylori- eradicated patients (%)Number of patients with platelet response (%)
Europe10 [151-160]495288 (58.2)242222 (91.7)108 (48.6)
Asia28 [161-188]15251089 (71.4)929811 (87.3)472 (58.2)
America2 [189, 190]5433 (90.6)3329 (87.9)24 (82.8)
Worldwide total40 [151-190]20741410 (68.0)12041062 (88.2)604 (56.9)

Table 2.

Helicobacter pyloriand immune thrombocytopenia in adults

Source: Modified from Campuzano et al. [191]


Regarding to the association of H. pyloriinfection with ITP in children, it is important to clarify that childhood ITP has a different course than ITP in adults [135]. The few studies that have thus far addressed the relationship between ITP and H. pyloriin children are contradictory: certain groups in China [196], Japan [197], Iran [198], Finland [199], Netherlands [200], and Italy [201, 202] have identified an association between infection and ITP in children, with platelet count recovery in an average of 35.2% of the patients [191]. This rate is much lower than the response rate observed in adult patients with ITP, which is greater than 50% [151-190]. Meanwhile, other groups in Turkey [203], Italy [204, 205], Thailand [206], and Hungary [207] found no association and the response to eradication ranged from none [203, 204, 208] to very poor [205, 207].

2.3.2. Pathophysiology of secondary ITP (associated with H. pylori infection)

The origin of primary ITP is associated with congenital or acquired immune changes that lead to an immune system response against platelets or megakaryocytes that cannot be attributed to other causal changes. In secondary ITP, alternative primary events are identified that lead to the development of this autoimmune response [209]. In the case of H. pylorias causal agent of this disease, several mechanisms have been described that contribute to the development of the autoimmune response. One of these mechanisms is a change in the balance of Fcγ receptors, involved in the activation of monocytes, and their relation to the inhibitory Fc receptor FcγRIIB. H. pyloriinfection decreases the levels of FcγRIIB, leading to increased activated monocytes through Fcγ receptors, with elevated non-specific phagocytosis, resulting in overactivation of B and T lymphocytes. These results were confirmed by reversing monocyte activation following H. pylorieradication treatment, with reducing generation of autoantibodies by B lymphocytes and overactivation of innate and acquired autoimmune response, and increasing the amount of circulating platelets [179].

In conjunction with the overeactivation of monocytes, autoantibody production has also been described in ITP, which can opsonize the platelets and induce antibody-mediated phagocytosis by the reticuloendothelial system in the spleen. This response is attributed to molecular mimicry of infection-related bacterial proteins. The principal antigens associated with the autoimmune response against the platelets include the amino acid sequences of virulence factors such as VacA, CagA [17, 178] and urease B, which are present during H. pyloriinfection [210]. The similarities shared between these antigens and platelet surface glycoproteins, like the glycoprotein IIIa among other platelet antigens not yet identified, are associated with anti-CagA antibody production [178] and demonstrate the importance of H. pyloriinfection in ITP.

2.3.3. Management of ITP in the post-Helicobacter era

Concerning to the management of ITP in the post-Helicobacterera, it is important to clarify that H. pyloriis not the only cause of thrombocytopenia, and although the indication, investigation, and treatment of infection should be considered, it is no substitute for an adequate study of the etiologies more frequently associated with thrombocytopenia, which are particular to each region. The 40 series of cases previously discussed, a meta-analysis [211] and two systematic reviews [212, 213] demonstrated the burden of H. pyloriinfection on the development of ITP and that eradicating the infection improves the platelet count in more than 50% of the adult patients with chronic ITP [211-213]. This has permitted the scientific community, in particular the consensus and management guides of H. pyloriinfection, to include ITP as an indication for evaluating and eradicating the infection prior to proceeding with other traditional interventions in both adults and children [21, 23-30].

The American Society of Hematology (ASH) recognized H. pylorias a new cause of ITP and established to investigate and eradicate the bacteria during the basic evaluation of patients before applying conventional treatments for the disease [209]. In addition, the International Working Group for standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children, of the same Society, created a new ITP-associated group denominated “secondary ITP H. pylori–associated” [139]. Likewise, since 2003, the British Society for Haematology incorporated the study and eradication of H. pyloriinto their ITP management guidelines [140].

Figure 3.

Algorithm for the study and management of immune thrombocytopenia (ITP) in the post-Helicobacterera. (1) Before initiating treatment for a patient with ITP, an assessment of the prevalence ofH. pyloriinfection should be performed in each region. Generally, prevalence is high in developing countries and low in developed countries [1]. (2) If the rates ofH. pyloriinfection are low, proceed with a conventional management of ITP [140,209]. (3) If the rates ofH. pyloriinfection are high or the patient, despite living in a country where infection rates are low, comes from a country where the infection rates are high, proceed to determine the status ofH. pylorithrough a non-invasive test, ideally a 13C-urea breath test (13C-BUT) [27]. (4) If the patient is negative forH. pylori, investigate other causes of thrombocytopenia and treat conventionally [140,209]. (5) If the patient is positive forH. pylori, proceed with eradication of the infection [27]. (6) Confirm infection eradication 6–8 weeks after treatment using a non-invasive test, ideally a 13C-urea breath test [27]. (7) If eradication is not achieved, establish a new scheme of eradication therapy and continue treatment until it is achieved. (8) OnceH. pylorieradication is achieved, (9) if a platelet response is obtained (complete or partial remission), periodically evaluate the platelet count. (10) If there is no platelet response, proceed with a conventional management of ITP [140,209]. Reprinted from “Proof of an association betweenHelicobacter pyloriand idiopathic thrombocytopenic purpura in Latin America” by G. Campuzano-Maya, 2007,Helicobacter, 12, p. 270. Copyright 1999–2015 by John Wiley & Sons, Inc. Reprinted with author permission [189].

Before initiating treatment for a patient with ITP, an assessment of the prevalence of H. pyloriinfection should be performed according to the region. Generally, the prevalence is low in developed countries; these cases should proceed with conventional management of ITP [140, 209]. In developing countries, the rate of H. pyloriinfection is high; in these cases or when the patient, despite living in a country where infection rates are low, comes from a country where the infection rates are high, it should proceed to determine the status of H. pylorithrough a non-invasive test, ideally the 13C-urea breath test [27]. If the patient is negative for H. pylori, it is necessary to investigate other causes of thrombocytopenia and treat the patient conventionally [140, 209], whereas if the patient is positive for H. pyloriit is indispensable to eradicate the infection [27].

After 6–8 weeks of treatment, the infection eradication must be confirmed using a non-invasive test, ideally with 13C-urea breath test [27]. If eradication is not achieved, it is mandatory to establish a new therapy scheme until eradication is achieved. Once H. pylorieradication is achieved and obtained a platelet response (complete or partial remission), it is important to periodically evaluate platelet count. If there is no platelet response, it must establish a conventional management of ITP [140, 209].

Figure 3 shows a diagnostic and management algorithm for ITP in the post-Helicobacterera, taking into account the prevalence and status of H. pyloriinfection [189].

Advertisement

3. Hematological diseases not recognized as related to H. pylori

This group includes autoimmune neutropenia, antiphospholipid syndrome, Henoch–Schönlein purpura, plasma cell dyscrasias, such as monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma, and other diseases possibly associated or implicated, such as leukemia and hemorrhagic manifestations with hematologic origin, like congenital and acquired coagulopathies and anticoagulation.

3.1. Immune neutropenia

This association was first proposed in 2002 by Gupta et al. in England, who reported the case of a patient with neutropenia (400 neutrophils/µL) that rapidly returned to normal values following the eradication of H. pyloriinfection [214]. Since then, two new studies have been reported, which include eight and 69 patients [215, 216] and coincide with the original report of Gupta et al. [214]. In the future, it is recommended that in patients with neutropenia that is suspected of being immunological the H. pyloristatus be established and proceed to eradicate if positive [214] as part of good medical practice.

3.2. Antiphospholipid syndrome

Similarly to immune neutropenia, antiphospholipid syndrome, a coagulation disorder of immunologic origin characterized by both arterial and venous thrombosis and associated with pregnancy complications, such as abortion, premature childbirth, and pre-eclampsia [217], was proposed as an extragastric association of H. pyloriinfection in 2001 by Cicconi et al. in Italy. These authors reported the case of a woman in whom antiphospholipid syndrome disappeared after the eradication of H. pyloriinfection [218]. At the moment, there are no new reports of this association in the medical literature possibly only because it is not being considered or investigated. However, it is worth recalling that antiphospholipid syndrome has been associated with other diseases of immunologic origin that in turn are associated with H. pyloriinfection, such as ITP [189, 219, 220], systemic lupus erythematosus [221], and central serous chorioretinitis [222, 223].

3.3. Henoch–Schönlein purpura

Henoch–Schönlein purpura is an immunologic disease of unknown etiology manifested by small vessel leukocytoclastic vasculitis with deposits of immunoglobulin A (IgA) in the skin, joints, gastrointestinal tract, and kidneys [224]. Henoch–Schönlein purpura is included in this review because it is part of the differential diagnosis of thrombocytopenia, particularly ITP discussed previously, which manifests as purpuric lesions on the skin. The association of H. pyloriwith Henoch–Schönlein purpura was proposed in the case of a 21-year-old man by Rainauer et al. in Germany in 1996 [225]. Since then, many studies have confirmed the association in adults [226-231], children, and adolescents [229, 232, 233], with the disappearance of clinical manifestations in H. pylori-positive cases after eradication [229-231].

3.4. Plasma cell dyscrasias

Plasma cell dyscrasias are among the most frequent clonal diseases in elderly persons and include MGUS, multiple myeloma, solitary plasmacytoma, plasma cell leukemia, Waldenström’s macroglobulinemia, and other chronic myeloproliferative syndromes of B lymphocytes [234]. Plasma cell dyscrasias may present an asymptomatic course or pass from one disease to another; for example, MGUS, a completely benign and asymptomatic condition that does not require treatment, can transform into a more severe and potentially fatal disease, such as multiple myeloma [234].

The association of plasma cell dyscrasias with stomach diseases has been known for many years, before the discovery that the stomach could be colonized by bacteria [3]. Gastrointestinal plasmacytomas were documented by the father of modern medicine, Sir William Osler, in 1920 [235], and for many years, the association of these and multiple myeloma with pernicious anemia [236, 237] and gastric cancer [238-242], entities clearly correlated with H. pyloriinfection, has been known. Perhaps, the most important evidence of the association of H. pyloriinfection with plasma cell dyscrasias is that some plasmacytomas disappear after the eradication of H. pylori. The authors who have analyzed this facet of infection by H. pylorihave agreed to recommending that in all patients with these manifestations be offered the opportunity of evaluated and eradicate the infection if present [243-245]. Other associations described include a clear interaction between MALT lymphoma of the stomach and MGUS [246] as well as Waldenström’s disease and MALT [247].

The relation of multiple myeloma with gastric MALT type lymphomas [248-254] was identified many years before H. pyloriwas known. Today, it is known that in MALT lymphoma, H. pyloriantigens can also stimulate plasma cells. The plasmacytomas discussed previously could be the expression of a localized myeloma, and once disseminated, it would not be possible to differentiate one from another. Wöhrer at al. have shown an association of gastric lymphomas with gastric myelomas [255]; besides, they described a case of plasmacytoma of the orbit, which completely remitted after the eradication of H. pylori[256]. Therefore, it is logical that all patients with a disease diagnosis related to plasma cells should be studied for H. pyloriand if positive, be treated with eradication therapy prior to starting conventional treatment.

According to Malik et al., MGUS, important in the study of patients with plasma cell dyscrasia, may be related to H. pylorias result of chronic antigenic stimulation of B lymphocytes in the gastric mucosa by the bacteria. Resolution of the gammopathy is observed in up to 30% of cases by eradicating the bacteria [257], a relationship confirmed by some authors [246, 258] but not by others [215, 259].

3.5. Other hematologic manifestations

According to the medical literature, other hematologic manifestations demonstrate possible associations with H. pyloriinfection, which despite the low abundance of information entailed important clinical implications. Lehtine et al. reported that in Iceland, anti-H. pyloriimmunoglobulin G was associated with increased risk of childhood leukemia in offspring (OR = 2.8, 95% CI: 1.1–6.9), whereas in Finland, it is not associated. Because anti-H. pyloriimmunoglobulin G indicates chronic carriage of the bacteria, early colonization of the offspring probably differs between Iceland and Finland, two affluent countries [260]. This type of study should be replicated at other sites, especially those where the prevalence of H. pyloriis high, such as in Asian countries and Latin America. Diamantidis et al. reported that although there is no evidence for a causal relationship between H. pyloriinfection and myelodysplastic syndrome (MDS), an increased prevalence of H. pyloriinfection among MDS patients has been found. This is an interesting finding that deserves further investigation because it may indicate a common factor causing susceptibilities to both MDS and H. pyloriinfection or that H. pylorimight influence the pathophysiology of MDS [261]. Recently, Kawamata et al. described the case of a patient with H. pylori-induced thrombocytosis clinically indistinguishable from essential thrombocythemia, which disappeared after the eradication of the infection [262].

Another problem emerging in clinical practice is the inherent increased risk of hemorrhage in patients with hematologic diseases; H. pylori, according to preliminary studies, would be a risk factor for the occurrence of these events. This is the case for patients with acute leukemia who are infected with H. pylori: the risk of gastrointestinal hemorrhaging during treatment is greater than in non-infected patients. This would be reduced if all patients with leukemia are offered the screening and eradication of H. pyloriwhen treatment begins [263]. In patients with potentially hemorrhagic diseases, such as hemophilia (A and B) and von Willebrand’s disease, H. pyloriinfection should be considered as an important cause of upper gastrointestinal bleeding. It is recommended a stool antigen test as a new and non-invasive screening test for diagnosis of H. pyloriinfection in all patients with hereditary hemorrhagic disorders [264]. These procedures are cost efficient for the health system, if one takes into account that the screening, followed by treatment of all infected patients, yields a reduction of direct costs over a 5-year period of 130 US$ per screened patient [265]. Therefore, due to increased bleeding complications, H. pyloriscreening and therapy appear mandatory in patients with bleeding disorders [266]. This conduct would also be applicable for patients undergoing prophylactic anticoagulation therapy [267] like aspirin [95]. The study and eradication of H. pyloriin patients with chronic idiopathic neutropenia are also suggested, wherein splenomegaly, it is probably associated with H. pylori, as evidenced by correlation between splenic volume and infection period [215, 216].

Advertisement

4. Conclusions

The recognition of hematologic diseases associated with H. pyloriinfection and its incorporation as an indication for study and eradication in the consensus and management guides for H. pyloriinfection represent a profound paradigm shift in the management of these diseases and a great advance for humanity. In addition to the benefits that eradication brings to the infected people, especially those related to gastric cancer [4] and peptic ulcer disease [3], the paradigm shifts introduced into medical practice and the medico-social impact expected from these new paradigms are summarized in the following paragraphs.

4.1. Iron deficiency

The management of iron deficiency is palliative and based on iron supplementation [32], where there is often no impact on the direct cause associated with ferropenia [35]. With the incorporation of iron deficiency, with or without anemia, into the consensus and management guides for H. pyloriinfection as an indication to investigate and eradicate the bacteria [21-30], a new paradigm was generated, where the etiology of ferropenia can be infectious and the eradication of H. pylorimay be sufficient to cure the deficiency, in the strict sense of the word [46-50]. Under the new paradigm, where eradication of the infection corrects the iron deficiency, in addition to restoring health [46-50] and increasing productivity [32], the prevalence of H. pyloriinfection and the diseases associated with it, such as gastric cancer [4] and gastric acid disease [3], decreases.

4.2. Vitamin B12 deficiency

The management of vitamin B12 deficiency is also palliative and based on vitamin supplementation, where there is little impact on the initial cause of the deficiency [134]. With the incorporation of vitamin B12 deficiency into the consensus and management guides for H. pyloriinfection as an indication to investigate and eradicate the bacteria [27, 29], a new paradigm was generated, where the etiology of vitamin B12 deficiency can be infectious and the eradication of H. pylorimay be sufficient to correct it [127]. Under this new paradigm, where eradication of infection corrects the vitamin B12 deficiency by a curative rather than palliative treatment [127], the patient is released from a chronic disease [134] closely related to gastric cancer and from diverse diseases such as Alzheimer’s disease [107, 108], depression [111], stroke [112, 113], pulmonary embolism [114], acute myocardial infarction, and coronary heart disease [116], which are regulated through homocysteine and generate high morbidity, mortality, and costs for health systems.

4.3. Immune thrombocytopenia

The treatment of ITP is palliative, not curative, and is oriented toward controlling the production of antibodies against platelets using medication or through the removal of organs that sequester platelets, such as the spleen [140, 209]. With the incorporation of ITP into the consensus and management guides for H. pyloriinfection as an indication to investigate and eradicate the bacteria [21, 23-30], a new paradigm was generated, where the etiology of ITP can be infectious and the eradication of H. pylorimay be sufficient to cure it, in the strict sense of the word [151-190]. Under the new paradigm, where the eradication of infection leads to correction of the platelet count with definitive cure of ITP, the patient is freed from a chronic disease [140, 209] by a curative rather than palliative treatment [151-190]. Furthermore, the eradication of the infection in these patients reduces the prevalence of gastric cancer and peptic acid disease, with which it is closely related and which contribute to high morbidity, mortality, and costs for health systems.

Advertisement

Acknowledgments

The author gratefully acknowledges to Verónica Tangarife-Castaño for her insightful discussions and help with the English translation as well as the willingness and collaboration.

References

  1. 1. Pounder RE, Ng D. The prevalence ofHelicobacter pyloriinfection in different countries. Aliment Pharmacol Ther. 1995; 9 Suppl 2: 33–39.
  2. 2. EUROGAST Study Group. Epidemiology of, and risk factors for,Helicobacter pyloriinfection among 3194 asymptomatic subjects in 17 populations. Gut 1993; 34: 1672–1676.
  3. 3. Warren JR, Marshall B. Unidentified curved baccilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1:1273-1275.
  4. 4. Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013; 42: 211–217. DOI: 10.1016/j.gtc.2013.01.002.
  5. 5. Stolte M, Bayerdorffer E, Morgner A, Alpen B, Wundisch T, Thiede C, et al. Helicobacter and gastric MALT lymphoma. Gut 2002; 50 Suppl 3: III19–III24.
  6. 6. Gasbarrini A, Franceschi F, Armuzzi A, Ojetti V, Candelli M, Torre ES, et al. Extradigestive manifestations ofHelicobacter pylorigastric infection. Gut 1999; 45 Suppl 1: I9–I12.
  7. 7. Realdi G, Dore MP, Fastame L. Extradigestive manifestations ofHelicobacter pyloriinfection: fact and fiction. Dig Dis Sci. 1999; 44: 229–236.
  8. 8. Carloni E, Cremonini F, Di Caro S, Padalino C, Gerardino L, Santoliquido A, et al.Helicobacter pylori-related extradigestive diseases and effects of eradication therapy. Dig Liver Dis. 2000; 32 Suppl 3: S214–S216.
  9. 9. De Koster E, De Bruyne I, Langlet P, Deltenre M. Evidence based medicine and extradigestive manifestations ofHelicobacter pylori. Acta Gastroenterol Belg. 2000; 63: 388–392.
  10. 10. Sherman PM, Lin FY. Extradigestive manifestation ofHelicobacter pyloriinfection in children and adolescents. Can J Gastroenterol. 2005; 19: 421–424.
  11. 11. Solnick JV, Franceschi F, Roccarina D, Gasbarrini A. Extragastric manifestations ofHelicobacter pyloriinfection––other Helicobacter species. Helicobacter 2006; 11 Suppl 1: 46–51.
  12. 12. Bohr UR, Annibale B, Franceschi F, Roccarina D, Gasbarrini A. Extragastric manifestations ofHelicobacter pyloriinfection –– other Helicobacters. Helicobacter 2007; 12 Suppl 1: 45–53.
  13. 13. Moyaert H, Franceschi F, Roccarina D, Ducatelle R, Haesebrouck F, Gasbarrini A. Extragastric manifestations ofHelicobacter pyloriinfection: other Helicobacters. Helicobacter 2008; 13 Suppl 1: 47–57. DOI: 10.1111/j.1523-5378.2008.00634.x.
  14. 14. Pellicano R, Franceschi F, Saracco G, Fagoonee S, Roccarina D, Gasbarrini A. Helicobacters and extragastric diseases. Helicobacter 2009; 14 Suppl 1: 58–68. DOI: 10.1111/j.1523-5378.2009.00699.x.
  15. 15. Figura N, Franceschi F, Santucci A, Bernardini G, Gasbarrini G, Gasbarrini A. Extragastric manifestations ofHelicobacter pyloriinfection. Helicobacter 2010; 15 Suppl 1: 60–68. DOI: 10.1111/j.1523-5378.2010.00778.x.
  16. 16. Suzuki H, Franceschi F, Nishizawa T, Gasbarrini A. Extragastric manifestations ofHelicobacter pyloriinfection. Helicobacter 2011; 16 Suppl 1: 65–69. DOI: 10.1111/j.1523-5378.2011.00883.x.
  17. 17. Banic M, Franceschi F, Babic Z, Gasbarrini A. Extragastric manifestations ofHelicobacter pyloriinfection. Helicobacter 2012; 17 Suppl 1: 49–55. DOI: 10.1111/j.1523-5378.2012.00983.x.
  18. 18. Roubaud Baudron C, Franceschi F, Salles N, Gasbarrini A. Extragastric diseases andHelicobacter pylori. Helicobacter 2013; 18 Suppl 1: 44–51. DOI: 10.1111/hel.12077.
  19. 19. Pacifico L, Osborn JF, Tromba V, Romaggioli S, Bascetta S, Chiesa C.Helicobacter pyloriinfection and extragastric disorders in children: a critical update. World J Gastroenterol. 2014; 20: 1379–1401. DOI: 10.3748/wjg.v20.i6.1379.
  20. 20. Al Sayed A, Anand PS, Kamath KP, Patil S, Preethanath RS, Anil S. Oral cavity as an extragastric reservoir ofHelicobacter pylori. ISRN Gastroenterol. 2014; 2014: 261369. DOI: 10.1155/2014/261369.
  21. 21. Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management ofHelicobacter pyloriinfection: the Maastricht III Consensus Report. Gut. 2007; 56: 772–781. DOI: 10.1136/gut.2006.101634.
  22. 22. Chey WD, Wong BC. American College of Gastroenterology guideline on the management ofHelicobacter pyloriinfection. Am J Gastroenterol. 2007; 102: 1808–1825.
  23. 23. Caselli M, Zullo A, Maconi G, Parente F, Alvisi V, Casetti T, et al. Cervia II Working Group Report 2006: guidelines on diagnosis and treatment ofHelicobacter pyloriinfection in Italy. Dig Liver Dis. 2007; 39: 782–789.
  24. 24. Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. Diagnosis and treatment guidelines forHelicobacter pyloriinfection in Korea. Korean J Gastroenterol. 2009; 54: 269–278.
  25. 25. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia–Pacific Consensus Guidelines forHelicobacter pyloriinfection. J Gastroenterol Hepatol. 2009; 24: 1587–1600. DOI: 10.1111/j.1440-1746.2009.05982.x.
  26. 26. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, et al. Guidelines for the management ofHelicobacter pyloriinfection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1–20. DOI: 10.1111/j.1523-5378.2009.00738.x.
  27. 27. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management ofHelicobacter pyloriinfection––the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646–664. DOI: 10.1136/gutjnl-2012-302084.
  28. 28. Coelho LG, Maguinilk I, Zaterka S, Parente JM, Passos Mdo C, Moraes-Filho JP. 3th Brazilian Consensus onHelicobacter pylori. Arq Gastroenterol. 2013; 50: 81–96. DOI: 10.1590/S0004-28032013005000001.
  29. 29. Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, et al. III Spanish Consensus Conference onHelicobacter pyloriinfection. Gastroenterol Hepatol. 2013; 36: 340–374. DOI: 10.1016/j.gastrohep.2013.01.011.
  30. 30. Liu WZ, Xie Y, Cheng H, Lu NH, Hu FL, Zhang WD, et al. The Fourth Chinese National Consensus Report on the management ofHelicobacter pyloriinfection. J Dig Dis. 2013; 104: 516–518. DOI: 10.1111/1751-2980.12034.
  31. 31. Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, et al. Guidelines for the diagnosis and treatment ofHelicobacter pyloriinfection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014; 29: 1371–1386. DOI: 10.1111/jgh.12607.
  32. 32. WHO/UNICEF/UNU. Iron deficiency anemia assessment, prevention, and control. 2001. Available from: http://www.who.int/nutrition/publications/en/ida_assessment_prevention_control.pdf [accessed April 13, 2014].
  33. 33. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr. 2009; 12: 444–454. DOI: 10.1017/S1368980008002401.
  34. 34. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet 2007; 370: 511–520. DOI: 10.1016/S0140-6736(07)61235-5.
  35. 35. Goodnough LT, Nemeth E. Iron deficiency and related disorders. In: Greer JP, Arber DA, Glader B, List AF, Means RTJ, Paraskevas F, et al., editors. Wintrobe’s Clinical Hematology. 13 Ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. p. 617–642.
  36. 36. Blecker U, Renders F, Lanciers S, Vandenplas Y. Syncopes leading to the diagnosis of aHelicobacter pyloripositive chronic active haemorrhagic gastritis. Eur J Pediatr. 1991; 150: 560–561.
  37. 37. Bruel H, Dabadie A, Pouedras P, Gambert C, Le Gall E, Jezequel C. Revealing acute anemia ofHelicobacter pylorigastritis. Ann Pediatr (Paris). 1993; 40: 364–367.
  38. 38. Dufour C, Brisigotti M, Fabretti G, Luxardo P, Mori PG, Barabino A.Helicobacter pylorigastric infection and sideropenic refractory anemia. J Pediatr Gastroenterol Nutr. 1993; 17: 225–227.
  39. 39. Marignani M, Angeletti S, Bordi C, Malagnino F, Mancino C, Delle Fave G, et al. Reversal of long-standing iron deficiency anaemia after eradication ofHelicobacter pyloriinfection. Scand J Gastroenterol. 1997; 32: 617–622.
  40. 40. Milman N, Rosenstock S, Andersen L, Jorgensen T, Bonnevie O. Serum ferritin, hemoglobin, andHelicobacter pyloriinfection: a seroepidemiologic survey comprising 2794 Danish adults. Gastroenterology 1998; 115: 268–274.
  41. 41. Annibale B, Marignani M, Monarca B, Antonelli G, Marcheggiano A, Martino G, et al. Reversal of iron deficiency anemia afterHelicobacter pylorieradication in patients with asymptomatic gastritis. Ann Intern Med. 1999; 131: 668–672. DOI: 199911020-00006 pii.
  42. 42. Barabino A, Dufour C, Marino CE, Claudiani F, De Alessandri A. Unexplained refractory iron-deficiency anemia associated withHelicobacter pylorigastric infection in children: further clinical evidence. J Pediatr Gastroenterol Nutr. 1999; 28: 116–119.
  43. 43. Capurso G, Marignani M, Delle Fave G, Annibale B. Iron-deficiency anemia in premenopausal women: why not consider atrophic body gastritis andHelicobacter pylorirole? Am J Gastroenterol. 1999; 94: 3084–3085.
  44. 44. Peach HG, Bath NE, Farish SJ.Helicobacter pyloriinfection: an added stressor on iron status of women in the community. Med J Aust. 1998; 169: 188–190.
  45. 45. Collett JA, Burt MJ, Frampton CM, Yeo KH, Chapman TM, Buttimore RC, et al. Seroprevalence ofHelicobacter pyloriin the adult population of Christchurch: risk factors and relationship to dyspeptic symptoms and iron studies. N Z Med J. 1999; 112: 292–295.
  46. 46. Muhsen K, Cohen D.Helicobacter pyloriinfection and iron stores: a systematic review and meta-analysis. Helicobacter 2008; 13: 323–340. DOI: 10.1111/j.1523-5378.2008.00617.x.
  47. 47. Qu XH, Huang XL, Xiong P, Zhu CY, Huang YL, Lu LG, et al. DoesHelicobacter pyloriinfection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol. 2010; 16: 886–896.
  48. 48. Huang X, Qu X, Yan W, Huang Y, Cai M, Hu B, et al. Iron deficiency anaemia can be improved after eradication ofHelicobacter pylori. Postgrad Med J. 2010; 86: 272–278. DOI: 10.1136/pgmj.2009.089987.
  49. 49. Yuan W, Li Y, Yang K, Ma B, Guan Q, Wang D, et al. Iron deficiency anemia inHelicobacter pyloriinfection: meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2010; 45: 665–676. DOI: 10.3109/00365521003663670.
  50. 50. Zhang ZF, Yang N, Zhao G, Zhu L, Zhu Y, Wang LX. Effect ofHelicobacter pylorieradication on iron deficiency. Chin Med J (Engl). 2010; 123: 1924–1930.
  51. 51. Ashorn M, Ruuska T, Makipernaa A.Helicobacter pyloriand iron deficiency anaemia in children. Scand J Gastroenterol. 2001; 36: 701–705.
  52. 52. Seo JK, Ko JS, Choi KD. Serum ferritin andHelicobacter pyloriinfection in children: a sero-epidemiologic study in Korea. J Gastroenterol Hepatol. 2002; 17: 754–757.
  53. 53. Kostaki M, Fessatou S, Karpathios T. Refractory iron-deficiency anaemia due to silentHelicobacter pylorigastritis in children. Eur J Pediatr. 2003; 162: 177–179.
  54. 54. Huang LP, Zhuang ML, Bei GP, Gu CP, Li YH. Clinical study on the relation betweenHelicobacter pyloriinfection and iron-deficiency anemia in children. Zhonghua Liu Xing Bing Xue Za Zhi. 2004; 25: 458.
  55. 55. Yang YJ, Sheu BS, Lee SC, Yang HB, Wu JJ. Children ofHelicobacter pylori-infected dyspeptic mothers are predisposed toH. pyloriacquisition with subsequent iron deficiency and growth retardation. Helicobacter 2005; 10: 249–255.
  56. 56. Gessner BD, Baggett HC, Muth PT, Dunaway E, Gold BD, Feng Z, et al. A controlled, household-randomized, open-label trial of the effect that treatment ofHelicobacter pyloriinfection has on iron deficiency in children in rural Alaska. J Infect Dis. 2006; 193: 537–546.
  57. 57. Baggett HC, Parkinson AJ, Muth PT, Gold BD, Gessner BD. Endemic iron deficiency associated withHelicobacter pyloriinfection among school-aged children in Alaska. Pediatrics 2006; 117: e396–e404.
  58. 58. Süoglu OD, Gokce S, Saglam AT, Sokucu S, Saner G. Association ofHelicobacter pyloriinfection with gastroduodenal disease, epidemiologic factors and iron-deficiency anemia in Turkish children undergoing endoscopy, and impact on growth. Pediatr Int. 2007; 49: 858–863.
  59. 59. Sarker SA, Mahmud H, Davidsson L, Alam NH, Ahmed T, Alam N, et al. Causal relationship ofHelicobacter pyloriwith iron-deficiency anemia or failure of iron supplementation in children. Gastroenterology 2008; 135: 1534–1542. DOI: 10.1053/j.gastro.2008.07.030.
  60. 60. Haghi-Ashtiani MT, Monajemzadeh M, Motamed F, Mahjoub F, Sharifan M, Shahsiah R, et al. Anemia in children with and withoutHelicobacter pyloriinfection. Arch Med Res. 2008; 39: 536–540. DOI: 10.1016/j.arcmed.2008.04.005.
  61. 61. Choe YH, Lee JE, Kim SK. Effect ofHelicobacter pylorieradication on sideropenic refractory anaemia in adolescent girls withHelicobacter pyloriinfection. Acta Paediatr. 2000; 89: 154–157.
  62. 62. Choe YH, Kim SK, Hong YC. The relationship betweenHelicobacter pyloriinfection and iron deficiency: seroprevalence study in 937 pubescent children. Arch Dis Child. 2003; 88: 178.
  63. 63. Hershko C, Hoffbrand AV, Keret D, Souroujon M, Maschler I, Monselise Y, et al. Role of autoimmune gastritis,Helicobacter pyloriand celiac disease in refractory or unexplained iron deficiency anemia. Haematologica 2005; 90: 585–595.
  64. 64. Parkinson AJ, Gold BD, Bulkow L, Wainwright RB, Swaminathan B, Khanna B, et al. High prevalence ofHelicobacter pyloriin the Alaska native population and association with low serum ferritin levels in young adults. Clin Diagn Lab Immunol. 2000; 7: 885–888.
  65. 65. Berg G, Bode G, Blettner M, Boeing H, Brenner H.Helicobacter pyloriinfection and serum ferritin: a population-based study among 1806 adults in Germany. Am J Gastroenterol. 2001; 96: 1014–1018.
  66. 66. Bini EJ.Helicobacter pyloriand iron deficiency anemia: guilty as charged? Am J Med. 2001; 111: 495–497.
  67. 67. Cuoco L, Cammarota G, Jorizzo RA, Santarelli L, Cianci R, Montalto M, et al. Link betweenHelicobacter pyloriinfection and iron-deficiency anaemia in patients with coeliac disease. Scand J Gastroenterol. 2001; 36: 1284–1288.
  68. 68. Choe YH, Kwon YS, Jung MK, Kang SK, Hwang TS, Hong YC.Helicobacter pylori-associated iron-deficiency anemia in adolescent female athletes. J Pediatr. 2001; 139: 100–104.
  69. 69. Yoshimura M, Hirai M, Tanaka N, Kasahara Y, Hosokawa O. Remission of severe anemia persisting for over 20 years after eradication ofHelicobacter pyloriin cases of Ménétrier’s disease and atrophic gastritis:Helicobacter pylorias a pathogenic factor in iron-deficiency anemia. Intern Med. 2003; 42: 971–977.
  70. 70. Nahon S, Lahmek P, Massard J, Lesgourgues B, Mariaud de Serre N, Traissac L, et al.Helicobacter pylori-associated chronic gastritis and unexplained iron deficiency anemia: a reliable association? Helicobacter 2003; 8: 573–577.
  71. 71. Ciacci C, Sabbatini F, Cavallaro R, Castiglione F, Di Bella S, Iovino P, et al.Helicobacter pyloriimpairs iron absorption in infected individuals. Dig Liver Dis. 2004; 36: 455–460.
  72. 72. Valiyaveettil AN, Hamide A, Bobby Z, Krishnan R. Effect of anti-Helicobacter pyloritherapy on outcome of iron-deficiency anemia: a randomized, controlled study. Indian J Gastroenterol. 2005; 24: 155–157.
  73. 73. Cardenas VM, Mulla ZD, Ortiz M, Graham DY. Iron deficiency andHelicobacter pyloriinfection in the United States. Am J Epidemiol. 2006; 163: 127–134.
  74. 74. Chen LH, Luo HS. Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency anemia patients withH. pylori-positive chronic gastristis. World J Gastroenterol. 2007; 13: 5380–5383.
  75. 75. Vijayan G, Sundaram RC, Bobby Z, Hamide A, Selvaraj N, Dasse NR. Increased plasma malondialdehyde and fructosamine in anemicH. pyloriinfected patients: effect of treatment. World J Gastroenterol. 2007; 13: 796–800.
  76. 76. Kaffes A, Cullen J, Mitchell H, Katelaris PH. Effect ofHelicobacter pyloriinfection and low-dose aspirin use on iron stores in the elderly. J Gastroenterol Hepatol. 2003; 18: 1024–1028.
  77. 77. Mulayim B, Celik NY, Yanik FF.Helicobacter pyloriinfection detected by C-Urea breath test is associated with iron deficiency anemia in pregnant women. J Obstet Gynaecol Res. 2008; 34: 980–985. DOI: 10.1111/j.1447-0756.2008.00822.x.
  78. 78. Correa P, Piazuelo MB. Natural history ofHelicobacter pyloriinfection. Dig Liver Dis. 2008; 40: 490–496. DOI: 10.1016/j.dld.2008.02.035.
  79. 79. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001; 276: 7806–7810. DOI: 10.1074/jbc.M008922200.
  80. 80. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011; 57: 1650–1669. DOI: 10.1373/clinchem.2009.140053.
  81. 81. Cherian S, Forbes DA, Cook AG, Sanfilippo FM, Kemna EH, Swinkels DW, et al. An insight into the relationships between hepcidin, anemia, infections and inflammatory cytokines in pediatric refugees: a cross-sectional study. PLoS One. 2008; 3: e4030. DOI: 10.1371/journal.pone.0004030.
  82. 82. Hershko C, Ronson A. Iron deficiency, Helicobacter infection and gastritis. Acta Haematol. 2009; 122: 97–102. DOI: 10.1159/000243793.
  83. 83. Lee SY, Song EY, Yun YM, Yoon SY, Cho YH, Kim SY, et al. Serum prohepcidin levels inHelicobacter pyloriinfected patients with iron deficiency anemia. Korean J Intern Med. 2010; 25: 195–200. DOI: 10.3904/kjim.2010.25.2.195.
  84. 84. Schwarz P, Kubler JA, Strnad P, Muller K, Barth TF, Gerloff A, et al. Hepcidin is localised in gastric parietal cells, regulates acid secretion and is induced byHelicobacter pyloriinfection. Gut. 2012; 61: 193–201. DOI: 10.1136/gut.2011.241208.
  85. 85. Ozkasap S, Yarali N, Isik P, Bay A, Kara A, Tunc B. The role of prohepcidin in anemia due toHelicobacter pyloriinfection. Pediatr Hematol Oncol. 2013; 30: 425–431. DOI: 10.3109/08880018.2013.783144.
  86. 86. Emiralioglu N, Yenicesu I, Sari S, Egritas O, Poyraz A, Pasaoglu OT, et al. An insight into the relationships between prohepcidin, iron deficiency anemia, and interleukin-6 values in pediatricHelicobacter pylorigastritis. Eur J Pediatr. 2015; 174: 903-910. DOI: 10.1007/s00431-014-2482-4.
  87. 87. Sato Y, Yoneyama O, Azumaya M, Takeuchi M, Sasaki SY, Yokoyama J, et al. The relationship between iron deficiency in patients withHelicobacter pylori-infected nodular gastritis and the serum prohepcidin level. Helicobacter 2015; 20: 11–18. DOI: 10.1111/hel.12170.
  88. 88. Azab SF, Esh AM. Serum hepcidin levels inHelicobacter pylori-infected children with iron-deficiency anemia: a case-control study. Ann Hematol. 2013; 92: 1477–1483. DOI: 10.1007/s00277-013-1813-2.
  89. 89. Yip R, Limburg PJ, Ahlquist DA, Carpenter HA, O’Neill A, Kruse D, et al. Pervasive occult gastrointestinal bleeding in an Alaska native population with prevalent iron deficiency. Role ofHelicobacter pylorigastritis. JAMA 1997; 277: 1135–1139.
  90. 90. Kang JM, Kim N, Lee BH, Park HK, Jo HJ, Shin CM, et al. Risk factors for peptic ulcer bleeding in terms ofHelicobacter pylori, NSAIDs, and antiplatelet agents. Scand J Gastroenterol. 2011; 46: 1295–1301. DOI: 10.3109/00365521.2011.605468.
  91. 91. Musumba C, Jorgensen A, Sutton L, Van Eker D, Moorcroft J, Hopkins M, et al. The relative contribution of NSAIDs andHelicobacter pylorito the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Aliment Pharmacol Ther. 2012; 36: 48–56. DOI: 10.1111/j.1365-2036.2012.05118.x.
  92. 92. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role ofHelicobacter pylorieradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005; 21: 1411–1418.
  93. 93. De Leest HT, Steen KS, Bloemena E, Lems WF, Kuipers EJ, Van de Laar MA, et al.Helicobacter pylorieradication in patients on long-term treatment with NSAIDs reduces the severity of gastritis: a randomized controlled trial. J Clin Gastroenterol. 2009; 43: 140–146. DOI: 10.1097/MCG.0b013e3181595b40.
  94. 94. Sokic-Milutinovic A, Krstic M, Rozer-Smolovic B, Alempijevic T. Role ofHelicobacter pyloriinfection in gastroduodenal damage in patients starting NSAID therapy: 4 Months follow-up study. Dig Dis Sci. 2010; 55: 2887–2892. DOI: 10.1007/s10620-009-1097-5.
  95. 95. Song HJ, Kwon JW, Kim N, Park YS. Cost effectiveness associated withHelicobacter pyloriscreening and eradication in patients taking nonsteroidal anti-inflammatory drugs and/or aspirin. Gut Liver. 2013; 7: 182–189. DOI: 10.5009/gnl.2013.7.2.182.
  96. 96. Afifi MT, Abd El–Aziz HK, Hamed NA, Barghash NA, Abdo A, Gamal M. Role ofHelicobacter pyloriin refractory iron deficiency anaemia. Br J Biomed Sci. 2009; 66: 133–136.
  97. 97. Boyanova L. Role ofHelicobacter pylorivirulence factors for iron acquisition from gastric epithelial cells of the host and impact on bacterial colonization. Future Microbiol. 2011; 6: 843–846. DOI: 10.2217/fmb.11.75.
  98. 98. Ge R, Sun X. Iron trafficking system inHelicobacter pylori. Biometals 2012; 25: 247–258. DOI: 10.1007/s10534-011-9512-8.
  99. 99. Davis RE. Clinical chemistry of vitamin B12. Adv Clin Chem. 1985; 24: 163–216.
  100. 100. Herbert V. Staging vitamin B12 (cobalamin) status in vegetarians. Am J Clin Nutr. 1994; 59: 1213S–1222S.
  101. 101. Andrés E, Loukili NH, Noel E, Kaltenbach G, Abdelgheni MB, Perrin AE, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ 2004; 171: 251–259.
  102. 102. Dali-Youcef N, Andres E. An update on cobalamin deficiency in adults. QJM 2009; 102: 17–28. DOI: 10.1093/qjmed/hcn138.
  103. 103. Carmel R, Johnson CS, Weiner JM. Pernicious anemia in Latin Americans is not a disease of the elderly. Arch Intern Med. 1987; 147: 1995–1996.
  104. 104. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med. 1996; 156: 1097–1100.
  105. 105. Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med. 1997; 337: 1441–1448.
  106. 106. Jimenez C, Bustos M, Besses C. The irreplaceable image: a patient with subacute degeneration of the spinal cord secondary to pernicious anemia. Haematologica 2001; 86: 444.
  107. 107. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002; 346: 476–483.
  108. 108. Hooshmand B, Solomon A, Kareholt I, Leiviska J, Rusanen M, Ahtiluoto S, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology 2010; 75: 1408–1414. DOI: 10.1212/WNL.0b013e3181f88162.
  109. 109. Werder SF. Cobalamin deficiency, hyperhomocysteinemia, and dementia. Neuropsychiatr Dis Treat. 2010; 6: 159–195.
  110. 110. Hooshmand B, Solomon A, Kareholt I, Rusanen M, Hanninen T, Leiviska J, et al. Associations between serum homocysteine, holotranscobalamin, folate and cognition in the elderly: a longitudinal study. J Intern Med. 2012; 271: 204–212. DOI: 10.1111/j.1365-2796.2011.02484.x.
  111. 111. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MM. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiat. 2002; 159: 2099–2101.
  112. 112. Kaptan K, Beyan C. Does hyperhomocysteinemia due to vitamin B12 deficiency associated withHelicobacter pyloriinfection has a role on cerebral stroke? Med Sci Monit. 2002; 8: LE52–LE53; author reply LE53.
  113. 113. Moghaddasi M, Mamarabadi M, Mirzadeh S, Freydoonnejad AA, Razjouyan H. Homocysteine, vitamin B12 and folate levels in Iranian patients with ischemic stroke. Neurol Res. 2010; 32: 953–956. DOI: 10.1179/016164110X12644252260475.
  114. 114. Caldera A, Mora J, Kotler M, Eiger G. Pulmonary embolism in a patient with pernicious anemia and hyperhomocysteinemia. Chest 2002; 122: 1487–1488.
  115. 115. Andrés E, Kurtz JE. Pulmonary embolism in pernicious anemia and hyperhomocysteinemia. Chest 2003; 124: 1181.
  116. 116. Whincup PH, Mendall MA, Perry IJ, Strachan DP. Hyperhomocysteinaemia,Helicobacter pylori, and coronary heart disease. Heart 1997; 78: 524.
  117. 117. O’Connor HJ, Axon AT, Dixon MF. Campylobacter–like organisms unusual in type A (pernicious anaemia) gastritis. Lancet 1984; 2: 1091.
  118. 118. Fong TL, Dooley CP, Dehesa M, Cohen H, Carmel R, Fitzgibbons PL, et al.Helicobacter pyloriinfection in pernicious anemia: a prospective controlled study. Gastroenterology 1991; 100: 328–332.
  119. 119. Saito M, Mori A, Irie T, Tanaka M, Morioka M.Helicobacter pyloriinfection is not associated with pernicious anemia in Japan. Rinsho Ketsueki. 2008; 49: 1569–1571. DOI: JST.JSTAGE/rinketsu/49.1569 pii.
  120. 120. Blaser MJ, Perez-Perez GI, Lindenbaum J, Schneidman D, Van Deventer G, Marin-Sorensen M, et al. Association of infection due toHelicobacter pyloriwith specific upper gastrointestinal pathology. Rev Infect Dis. 1991; 13 Suppl 8: S704–S708.
  121. 121. Suter PM, Golner BB, Goldin BR, Morrow FD, Russell RM. Reversal of protein-bound vitamin B12 malabsorption with antibiotics in atrophic gastritis. Gastroenterology 1991; 101: 1039–1045.
  122. 122. Valle J, Kekki M, Sipponen P, Ihamaki T, Siurala M. Long-term course and consequences ofHelicobacter pylorigastritis. Results of a 32-year follow-up study. Scand J Gastroenterol. 1996; 31: 546–550.
  123. 123. Claeys D, Faller G, Appelmelk BJ, Negrini R, Kirchner T. The gastric H+,K+-ATPase is a major autoantigen in chronicHelicobacter pylorigastritis with body mucosa atrophy. Gastroenterology 1998; 115: 340–347.
  124. 124. Kokkola A, Kosunen TU, Puolakkainen P, Sipponen P, Harkonen M, Laxen F, et al. Spontaneous disappearance ofHelicobacter pyloriantibodies in patients with advanced atrophic corpus gastritis. Apmis 2003; 111: 619–624.
  125. 125. Carmel R. Current concepts in cobalamin deficiency. Annu Rev Med. 2000; 51: 357–375. DOI: 10.1146/annurev.med.51.1.357.
  126. 126. Kaptan K, Beyan C, Ural AU, Cetin T, Avcu F, Gulsen M, et al.Helicobacter pylori––is it a novel causative agent in Vitamin B12 deficiency? Arch Intern Med. 2000; 160: 1349–1353.
  127. 127. Marino MC, de Oliveira CA, Rocha AM, Rocha GA, Clementino NC, Antunes LF, et al. Long-term effect ofHelicobacter pylorieradication on plasma homocysteine in elderly patients with cobalamin deficiency. Gut. 2007; 56: 469–474.
  128. 128. Lahner E, Persechino S, Annibale B. Micronutrients (other than iron) andHelicobacter pyloriinfection: a systematic review. Helicobacter 2012; 17: 1–15. DOI: 10.1111/j.1523-5378.2011.00892.x.
  129. 129. Kaplan HS, Rigler LG. Pernicious anemia and susceptibility to gastric neoplasms. J Lab Clin Med. 1947; 32: 644–653.
  130. 130. Zamcheck N, Grable E, Ley A, Norman L. Occurrence of gastric cancer among patients with pernicious anemia at the Boston City Hospital. N Engl J Med. 1955; 252: 1103–1110.
  131. 131. Berkson J, Comfort MW, Butt HR. Occurrence of gastric cancer in persons with achlorhydria and eith pernicious anemia. Proc Staff Meet Mayo Clin. 1956; 31: 583–596.
  132. 132. Payne RW. Pernicious anaemia and gastric cancer in England and Wales. Br Med J. 1961; 1: 1807–1809.
  133. 133. Vannella L, Lahner E, Osborn J, Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther. 2013; 37: 375–382. DOI: 10.1111/apt.12177.
  134. 134. Carmel R. Megaloblastic anemias: disorders of impaired DNA synthesis. In: Greer JP, Arber DA, Glader B, List AF, Means RTJ, Paraskevas F, et al., editors. Wintrobe’s Clinical Hematology. 13 Ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. p. 927–953.
  135. 135. Liel MS, Carverley DC. Thrombopcytopenia caused by immunologic platelet destruction In: Greer JP, Arber DA, Glader B, List AF, Means RTJ, Paraskevas F, et al., editors. Wintrobe’s Clinical Hematology. 13 Ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. p. 1061–1076.
  136. 136. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999; 94: 909–913.
  137. 137. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Jr., Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190–4207. DOI: 10.1182/blood-2010-08-302984.
  138. 138. Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood 1984; 64: 1179–1183.
  139. 139. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386–2393. DOI: 10.1182/blood-2008-07-162503.
  140. 140. British Society for Haematology. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003; 120: 574–596.
  141. 141. García-Pérez A, Valverde de La Osa J, Giménez Samper M, Alonso García I. Resolution of an autoimmune thrombocytopenic purpura after eradicating treatment ofHelicobacter pylori. Sangre (Barc). 1999; 44: 387–388.
  142. 142. Tohda S, Ohkusa T. Resolution of refractory idiopathic thrombocytopenic purpura after eradication ofHelicobacter pylori. Am J Hematol. 2000; 65: 329–330.
  143. 143. Goto H, Kikuta T, Ota A, Tsuji H, Hino R. Successful treatment of refractory idiopathic thrombocytopenic purpura by eradication ofHelicobacter pylori. Rinsho Ketsueki. 2001; 42: 1192–1194.
  144. 144. Mukai M, Kon Y, Notoya A, Kohno M.Helicobacter pyloriassociated with idiopathic thrombocytopenic purpura. Am J Med. 2002; 113: 169–171.
  145. 145. Asaumi N, Niiya K, Shibakura M, Yoshida C, Niiya M, Tanimoto M. Secondary eradication ofHelicobacter pyloriwas effective against refractory idiopathic thrombocytopenic purpura. Blood Coagul Fibrinolysis. 2003; 14: 785–786.
  146. 146. Takechi T, Unemoto J, Ishihara M, Hosokawa T, Zushi N, Shiraishi T, et al. Idiopathic thrombocytopenic purpura associated withHelicobacter pyloriinfection. Pediatr Int. 2006; 48: 76–78.
  147. 147. Grimaz S, Damiani D, Brosolo P, Skert C, Geromin A, de Pretis G. Resolution of thrombocytopenia after treatment forHelicobacter pylori: a case report. Haematologica 1999; 84: 283–284.
  148. 148. Soldinger E, Pilia MC, Piubello W, Nadali G. Multi-resistant idiopathic thrombocytopenia successfully treated by eradication ofHelicobacter pylori. Dig Liver Dis. 2001; 33: 732.
  149. 149. Candelli M, Nista EC, Pignataro G, Gasbarrini G, Gasbarrini A. Idiopathic thrombocytopenic purpura andHelicobacter pyloriinfection. Scand J Gastroenterol. 2003; 38: 569–570.
  150. 150. Kurekci AE, Atay AA, Sarici SU, Ozcan O. Complete platelet recovery after treatment ofHelicobacter pyloriinfection in a child with chronic immune thrombocytopenic purpura: a case report. Pediatr Hematol Oncol. 2004; 21: 593–596.
  151. 151. Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication ofHelicobacter pylori. Lancet 1998; 352: 878.
  152. 152. Emilia G, Longo G, Luppi M, Gandini G, Morselli M, Ferrara L, et al.Helicobacter pylorieradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood 2001; 97: 812–814.
  153. 153. Emilia G, Luppi M, Morselli M, Potenza L, D’Apollo N, Torelli G.Helicobacter pyloriinfection and idiopathic thrombocytopenic purpura. Br J Haematol. 2002; 118: 1198–1199.
  154. 154. Veneri D, Franchini M, Gottardi M, D'Adda M, Ambrosetti A, Krampera M, et al. Efficacy ofHelicobacter pylorieradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. Haematologica 2002; 87: 1177–1179.
  155. 155. Veneri D, Franchini M. Onset of Idiopathic Thrombocythemia afterHelicobacter pyloriEradication. Helicobacter 2005; 10: 95.
  156. 156. Stasi R, Rossi Z, Stipa E, Amadori S, Newland AC, Provan D.Helicobacter pylorieradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med. 2005; 118: 414–419.
  157. 157. Emilia G, Luppi M, Zucchini P, Morselli M, Potenza L, Forghieri F, et al.Helicobacter pyloriinfection and chronic immune thrombocytopenic purpura: long–term results of bacterium eradication and association with bacterium virulence profiles. Blood 2007; 110: 3833–3841. DOI: 10.1182/blood-2006-12-063222.
  158. 158. Scandellari R, Allemand E, Vettore S, Plebani M, Randi ML, Fabris F. Platelet response toHelicobacter pylorieradication therapy in adult chronic idiopathic thrombocytopenic purpura seems to be related to the presence of anticytotoxin-associated gene A antibodies. Blood Coagul Fibrinolysis. 2009; 20: 108–113. DOI: 10.1097/MBC.0b013e32832315d8.
  159. 159. Sayan O, Akyol Erikci A, Ozturk A. The Efficacy ofHelicobacter pylorieradication in the treatment of idiopathic thrombocytopenic purpura––the first study in Turkey. Acta Haematol. 2006; 116: 146–149. DOI: 10.1159/000093648.
  160. 160. Suvajdzic N, Stankovic B, Artiko V, Cvejic T, Bulat V, Bakrac M, et al.Helicobacter pylorieradication can induce platelet recovery in chronic idiopathic thrombocytopenic purpura. Platelets 2006; 17: 227–230.
  161. 161. Kohda K, Kuga T, Kogawa K, Kanisawa Y, Koike K, Kuroiwa G, et al. Effect ofHelicobacter pylorieradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br J Haematol. 2002; 118: 584–588.
  162. 162. Kohda K, Niitsu Y.Helicobacter pyloriinfection and idiopathic thrombocytopenic purpura. Nippon Rinsho. 2003; 61: 644–649.
  163. 163. Ando K, Shimamoto T, Tauchi T, Ito Y, Kuriyama Y, Gotoh A, et al. Can eradication therapy forHelicobacter pylorireally improve the thrombocytopenia in idiopathic thrombocytopenic purpura? Our experience and a literature review. Int J Hematol. 2003; 77: 239–244.
  164. 164. Hashino S, Mori A, Suzuki S, Izumiyama K, Kahata K, Yonezumi M, et al. Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication ofHelicobacter pylori. Int J Hematol. 2003; 77: 188–191.
  165. 165. Hino M, Yamane T, Park K, Takubo T, Ohta K, Kitagawa S, et al. Platelet recovery after eradication ofHelicobacter pyloriin patients with idiopathic thrombocytopenic purpura. Ann Hematol. 2003; 82: 30–32.
  166. 166. Kato A, Kato H, Hirashima N, Sakamoto T, Nukaya H, Ito K, et al. Evaluation of the efficacy of anHelicobacter pylorieradication treatment for idiopathic thrombocytopenic purpura patients. Nippon Shokakibyo Gakkai Zasshi. 2004; 101: 1209–1216.
  167. 167. Ando T, Tsuzuki T, Mizuno T, Minami M, Ina K, Kusugami K, et al. Characteristics ofHelicobacter pylori-induced gastritis and the effect ofH. pylorieradication in patients with chronic idiopathic thrombocytopenic purpura. Helicobacter 2004; 9: 443–452.
  168. 168. Nomura S, Inami N, Kanazawa S. The effects ofHelicobacter pylorieradication on chemokine production in patients with immune thrombocytopenic purpura. Eur J Haematol. 2004; 72: 304–305.
  169. 169. Sato R, Murakami K, Watanabe K, Okimoto T, Miyajima H, Ogata M, et al. Effect ofHelicobacter pylorieradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch Intern Med. 2004; 164: 1904–1907.
  170. 170. Takahashi T, Yujiri T, Shinohara K, Inoue Y, Sato Y, Fujii Y, et al. Molecular mimicry byHelicobacter pyloriCagA protein may be involved in the pathogenesis ofH. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2004; 124: 91–96.
  171. 171. Fujimura K.Helicobacter pyloriinfection and idiopathic thrombocytopenic purpura. Int J Hematol. 2005; 81: 113–118.
  172. 172. Inaba T, Mizuno M, Take S, Suwaki K, Honda T, Kawai K, et al. Eradication ofHelicobacter pyloriincreases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. Eur J Clin Invest. 2005; 35: 214–219.
  173. 173. Tsutsumi Y, Kanamori H, Yamato H, Ehira N, Kawamura T, Umehara S, et al. Randomized study ofHelicobacter pylorieradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura. Ann Hematol. 2005; 84: 807–811.
  174. 174. Suzuki T, Matsushima M, Masui A, Watanabe K, Takagi A, Ogawa Y, et al. Effect ofHelicobacter pylorieradication in patients with chronic idiopathic thrombocytopenic purpura–a randomized controlled trial. Am J Gastroenterol. 2005; 100: 1265–1270.
  175. 175. Asahi A, Kuwana M, Suzuki H, Hibi T, Kawakami Y, Ikeda Y. Effects of aHelicobacter pylorieradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica 2006; 91: 1436–1437.
  176. 176. Ishiyama M, Teramura M, Iwabe K, Kato T, Motoji T. Clonally expanded T-cells in the peripheral blood of patients with idiopathic thrombocytopenic purpura andHelicobacter pyloriinfection. Int J Hematol. 2006; 83: 147–151.
  177. 177. Satake M, Nishikawa J, Fukagawa Y, Akashi K, Okamoto T, Yoshida T, et al. The long-term efficacy ofHelicobacter pylorieradication therapy in patients with idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol. 2007; 22: 2233–2237. DOI: 10.1111/j.1440-1746.2007.04845.x.
  178. 178. Kodama M, Kitadai Y, Ito M, Kai H, Masuda H, Tanaka S, et al. Immune Response to CagA protein is associated with improved platelet count afterHelicobacter pylorieradication in patients with idiopathic thrombocytopenic purpura. Helicobacter 2007; 12: 36–42.
  179. 179. Asahi A, Nishimoto T, Okazaki Y, Suzuki H, Masaoka T, Kawakami Y, et al.Helicobacter pylorieradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. J Clin Invest. 2008; 118: 2939–2949. DOI: 10.1172/JCI34496.
  180. 180. Suzuki T, Matsushima M, Shirakura K, Koike J, Masui A, Takagi A, et al. Association of inflammatory cytokine gene polymorphisms with platelet recovery in idiopathic thrombocytopenic purpura patients after the eradication ofHelicobacter pylori. Digestion 2008; 77: 73–78. DOI: 10.1159/000121392.
  181. 181. Tsumoto C, Tominaga K, Okazaki H, Tanigawa T, Yamagami H, Watanabe K, et al. Long-term efficacy ofHelicobacter pylorieradication in patients with idiopathic thrombocytopenic purpura: 7-year follow-up prospective study. Ann Hematol. 2009; 88: 789–793. DOI: 10.1007/s00277-008-0667-5.
  182. 182. Sato R, Murakami K, Okimoto T, Watanabe K, Kodama M, Fujioka T. Development of corpus atrophic gastritis may be associated withHelicobacter pylori-related idiopathic thrombocytopenic purpura. J Gastroenterol. 2011; 46: 991–997. DOI: 10.1007/s00535-011-0416-8.
  183. 183. Kikuchi T, Kobayashi T, Yamashita T, Ohashi K, Sakamaki H, Akiyama H. Eight-year follow-up of patients with immune thrombocytopenic purpura related toH. pyloriinfection. Platelets 2011; 22: 59–62. DOI: 10.3109/09537104.2010.515272.
  184. 184. Kong R, Qiu HC, Wu PF, Niu XH, Shen WX, Wang Y. Clinical significance ofHelicobacter pyloriin pathogenesis of idiopathic thrombocytopenic purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008; 16: 1222–1226. DOI: 1009-2137(2008)05-1222-05 pii.
  185. 185. Wu S, Li Y, Jian Z, Tang F. Anti-Helicobacter pyloritreatment in patients with idiopathic thrombocytopenic purpura. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009; 34: 1251–1254.
  186. 186. Rostami N, Keshtkar-Jahromi M, Rahnavardi M, Esfahani FS. Effect of eradication ofHelicobacter pylorion platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial. Am J Hematol. 2008; 83: 376–381. DOI: 10.1002/ajh.21125.
  187. 187. Payandeh M, Sohrabi N, Zare ME, Kansestani AN, Hashemian AH. Platelet count response toHelicobacter pylorieradication in Iranian patients with idiopathic thrombocytopenic purpura. Mediterr J Hematol Infect Dis. 2012; 4: e2012056. DOI: 10.4084/MJHID.2012.056.
  188. 188. Tag HS, Lee HS, Jung SH, Kim BK, Kim SB, Lee A, et al. Effects ofHelicobacter pylorieradication in patients with immune thrombocytopenic purpura. Korean J Hematol. 2010; 45: 127–132. DOI: 10.5045/kjh.2010.45.2.127.
  189. 189. Campuzano-Maya G. Proof of an association betweenHelicobacter pyloriand idiopathic thrombocytopenic purpura in Latin America. Helicobacter 2007; 12: 265–273. DOI: 10.1111/j.1523-5378.2007.00502.x.
  190. 190. Jackson SC, Beck P, Buret AG, O’Connor PM, Meddings J, Pineo G, et al. Long term platelet responses toHelicobacter pylorieradication in Canadian patients with immune thrombocytopenic purpura. Int J Hematol. 2008; 88: 212–218. DOI: 10.1007/s12185-008-0138-8.
  191. 191. Campuzano-Maya G. Hematologic manifestations ofHelicobacter pyloriinfection. World J Gastroenterol. 2014; 20: 12818–12838. DOI: 10.3748/wjg.v20.i36.12818.
  192. 192. Jarque I, Andreu R, Llopis I, De la Rubia J, Gomis F, Senent L, et al. Absence of platelet response after eradication ofHelicobacter pyloriinfection in patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2001; 115: 1002–1003.
  193. 193. Michel M, Khellaf M, Desforges L, Lee K, Schaeffer A, Godeau B, et al. Autoimmune thrombocytopenic purpura andHelicobacter pyloriinfection. Arch Intern Med. 2002; 162: 1033–1036.
  194. 194. Ahn ER, Tiede MP, Jy W, Bidot CJ, Fontana V, Ahn YS. Platelet activation inHelicobacter pylori-associated idiopathic thrombocytopenic purpura: eradication reduces platelet activation but seldom improves platelet counts. Acta Haematol. 2006; 116: 19–24.
  195. 195. Estrada-Gomez RA, Parra-Ortega I, Martinez-Barreda C, Ruiz-Arguelles GJ.Helicobacter pyloriinfection and thrombocytopenia: a single-institution experience in Mexico. Rev Invest Clin. 2007; 59: 112–115.
  196. 196. Jaing TH, Yang CP, Hung IJ, Chiu CH, Chang KW. Efficacy ofHelicobacter pylorieradication on platelet recovery in children with chronic idiopathic thrombocytopenic purpura. Acta Paediatr. 2003; 92: 1153–1157.
  197. 197. Hayashi H, Okuda M, Aoyagi N, Yoshiyama M, Miyashiro E, Kounami S, et al.Helicobacter pyloriinfection in children with chronic idiopathic thrombocytopenic purpura. Pediatr Int. 2005; 47: 292–295.
  198. 198. Hamidieh AA, Arzanian MT, Gachkar L, Pasha F.Helicobacter pyloriinfection in children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2008; 30: 96–97. DOI: 10.1097/MPH.0b013e3181615600.
  199. 199. Rajantie J, Klemola T.Helicobacter pyloriand idiopathic thrombocytopenic purpura in children. Blood 2003; 101: 1660.
  200. 200. Neefjes VM, Heijboer H, Tamminga RY.H. pyloriinfection in childhood chronic immune thrombocytopenic purpura. Haematologica 2007; 92: 576.
  201. 201. Ferrara M, Capozzi L, Russo R. Influence ofHelicobacter pyloriinfection associated with iron deficiency anaemia on growth in pre-adolescent children. Hematology 2009; 14: 173–176. DOI: 10.1179/102453309X402287.
  202. 202. Russo G, Miraglia V, Branciforte F, Matarese SM, Zecca M, Bisogno G, et al. Effect of eradication ofHelicobacter pyloriin children with chronic immune thrombocytopenia: a prospective, controlled, multicenter study. Pediatr Blood Cancer. 2011; 56: 273–278. DOI: 10.1002/pbc.22770.
  203. 203. Yetgin S, Demir H, Arslan D, Unal S, Kocak N. Autoimmune thrombocytopenic purpura andHelicobacter pyloriinfection effectivity during childhood. Am J Hematol. 2005; 78: 318.
  204. 204. Loffredo G, Marzano MG, Migliorati R, Miele E, Menna F, Poggi V, et al. The relationship between immune thrombocytopenic purpura andHelicobacter pyloriinfection in children: where is the truth? Eur J Pediatr. 2007; 166: 1067–1068.
  205. 205. Bisogno G, Errigo G, Rossetti F, Sainati L, Pusiol A, Da Dalt L, et al. The role ofHelicobacter pyloriin children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2008; 30: 53–57. DOI: 10.1097/MPH.0b013e3181615613.
  206. 206. Teawtrakul N, Sawadpanich K, Sirijerachai C, Chansung K, Wanitpongpun C. Clinical characteristics and treatment outcomes in patients withHelicobacter pylori-positive chronic immune thrombocytopenic purpura. Platelets 2014; 25: 548–551. DOI: 10.3109/09537104.2013.841883.
  207. 207. Treepongkaruna S, Sirachainan N, Kanjanapongkul S, Winaichatsak A, Sirithorn S, Sumritsopak R, et al. Absence of platelet recovery followingHelicobacter pylorieradication in childhood chronic idiopathic thrombocytopenic purpura: a multi-center randomized controlled trial. Pediatr Blood Cancer. 2009; 53: 72–77. DOI: 10.1002/pbc.21991.
  208. 208. Veres G, Karoczkai I, Bodanszky H, Marosi A, Magyarossi E, Dezsofi A, et al. The role ofHelicobacter pyloriinfection in children with chronic immune thrombocytopenic purpura. Orv Hetil. 2009; 150: 801–804. DOI: 10.1556/OH.2009.28581.
  209. 209. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168–186. DOI: 10.1182/blood-2009-06-225565.
  210. 210. Bai Y, Wang Z, Bai X, Yu Z, Cao L, Zhang W, et al. Cross-reaction of antibody againstHelicobacter pyloriurease B with platelet glycoprotein IIIa and its significance in the pathogenesis of immune thrombocytopenic purpura. Int J Hematol. 2009; 89: 142–149. DOI: 10.1007/s12185-008-0247-4.
  211. 211. Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D. Effect ofHelicobacter pylorieradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother. 2007; 60: 237–246.
  212. 212. Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, et al. Effects of eradication ofHelicobacter pyloriinfection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113: 1231–1240. DOI: 10.1182/blood-2008-07-167155.
  213. 213. Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Liu Y, et al. Platelet count response toH. pyloritreatment in patients with immune thrombocytopenic purpura with and withoutH. pyloriinfection: a systematic review. Haematologica 2009; 94: 850–856. DOI: 10.3324/haematol.2008.005348.
  214. 214. Gupta V, Eden AJ, Mills MJ.Helicobacter pyloriand autoimmune neutropenia. Clin Lab Haematol. 2002; 24: 183–185.
  215. 215. Papadaki HA, Pontikoglou C, Stavroulaki E, Minadakis G, Eliopoulos DA, Pyrovolaki K, et al. High prevalence ofHelicobacter pyloriinfection and monoclonal gammopathy of undetermined significance in patients with chronic idiopathic neutropenia. Ann Hematol. 2005; 84: 317–320.
  216. 216. Papadaki HA, Pontikoglou C, Eliopoulos DG, Pyrovolaki K, Spyridaki R, Eliopoulos GD.Helicobacter pyloriinfection is probably the cause of chronic idiopathic neutropenia (CIN)-associated splenomegaly. Am J Hematol. 2006; 81: 142–144.
  217. 217. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006; 295: 1050–1057. DOI: 10.1001/jama.295.9.1050.
  218. 218. Cicconi V, Carloni E, Franceschi F, Nocente R, Silveri NG, Manna R, et al. Disappearance of antiphospholipid antibodies syndrome afterHelicobacter pylorieradication. Am J Med. 2001; 111: 163–164.
  219. 219. Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994; 84: 4203–4208.
  220. 220. Lipp E, von Felten A, Sax H, Muller D, Berchtold P. Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia. Eur J Haematol. 1998; 60: 283–288.
  221. 221. Macchi L, Rispal P, Clofent-Sanchez G, Pellegrin JL, Nurden P, Leng B, et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol. 1997; 98: 336–341.
  222. 222. Costen MT, Parkin BT, Davison CR, Crick MP. Central serous chorioretinopathy and antiphospholipid antibodies-results of a pilot study. Eye 2004; 18: 938.
  223. 223. Cotticelli L, Borrelli M, D’Alessio AC, Menzione M, Villani A, Piccolo G, et al. Central serous chorioretinopathy andHelicobacter pylori. Eur J Ophthalmol. 2006; 16: 274–278.
  224. 224. Gok F, Ugur Y, Ozen S, Dagdeviren A. Pathogenesis-related adhesion molecules in Henoch–Schönlein vasculitis. Rheumatol Int. 2008; 28: 313–316. DOI: 10.1007/s00296-007-0437-z.
  225. 225. Reinauer S, Megahed M, Goerz G, Ruzicka T, Borchard F, Susanto F, et al. Schönlein–Henoch purpura associated with gastricHelicobacter pyloriinfection. J Am Acad Dermatol. 1995; 33: 876–879.
  226. 226. Cecchi R, Torelli E. Schönlein–Henoch purpura in association with duodenal ulcer and gastricHelicobacter pyloriinfection. J Dermatol. 1998; 25: 482–484.
  227. 227. Novak J, Szekanecz Z, Sebesi J, Takats A, Demeter P, Bene L, et al. Elevated levels of anti-Helicobacter pyloriantibodies in Henoch–Schönlein purpura. Autoimmunity. 2003; 36: 307–311.
  228. 228. Fu KI, Yagi S, Mashimo Y, Sugitani K, Imamaki K, Yanagisawa M, et al. Regression ofHelicobacter pylori-negative duodenal ulcers complicated by Schönlein–Henoch purpura withH. pylorieradication therapy: the first report. Dig Dis Sci. 2005; 50: 381–384.
  229. 229. Mytinger JR, Patterson JW, Thibault ES, Webb J, Saulsbury FT. Henoch–Schönlein purpura associated withHelicobacter pyloriinfection in a child. Pediatr Dermatol. 2008; 25: 630–632. DOI: 10.1111/j.1525-1470.2008.00786.x.
  230. 230. Grivceva-Panovska V, Grivceva Stardelova K, Serafimoski V. Henoch–Schönlein purpura in an adult patient: extragastric, cutaneous manifestation ofHelicobacter pyloriinfection. Prilozi 2008; 29: 291–301.
  231. 231. Hoshino C. Adult onset Schönlein–Henoch purpura associated withHelicobacter pyloriinfection. Intern Med. 2009; 48: 847–851. DOI: JST.JSTAGE/internalmedicine/48.1718 pii.
  232. 232. Mozrzymas R, d’Amore ES, Montini G, Guariso G. Schönlein–Henoch vasculitis and chronicHelicobacter pyloriassociated gastritis and duodenal ulcer: a case report. Pediatr Med Chir. 1997; 19: 467–468.
  233. 233. Shin JI, Koh H, Lee JS. Henoch–Schönlein purpura associated withHelicobacter pyloriinfection: the pathogenic roles of IgA, C3, and cryoglobulins? Pediatr Dermatol. 2009; 26: 768–769. DOI: 10.1111/j.1525-1470.2009.01039.x.
  234. 234. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121: 749–757.
  235. 235. Osler W, McRae T, editors. Diseases of the stomach. The principles and practice of medicine. New York: Appleton; 1920. p. 425.
  236. 236. Twomey JJ, Laughter AH, Villanueva ND, Kao YS, Lidsky MD, Jordan PH, Jr. Gastric secretory and serologic studies on patients with neoplastic and immunologic disorders. Arch Intern Med. 1971; 128: 746–749.
  237. 237. Doberauer C, Sanner B, Henning B. Multiple myeloma involving the stomach with vitamin B12 deficiency. Eur J Gastroenterol Hepatol. 1999; 11: 205–207.
  238. 238. Chanarin I. The megaloblastic aenemias. 2 Ed. Oxford: Blackell Scientific Pubications; 1979.
  239. 239. Elsborg L, Mosbech J. Pernicious anaemia as a risk factor in gastric cancer. Acta Med Scand. 1979; 206: 315–318.
  240. 240. Borch K. Epidemiologic, clinicopathologic, and economic aspects of gastroscopic screening of patients with pernicious anemia. Scand J Gastroenterol. 1986; 21: 21–30.
  241. 241. Hsing AW, Hansson LE, McLaughlin JK, Nyren O, Blot WJ, Ekbom A, et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 1993; 71: 745–750.
  242. 242. Carmel R. Megaloblastic anemias: disorders of impaired DNA synthesis. In: Greer JP, Foerster J, Lukens J, Rodgers GM, Paraskevas F, Glader G, editors. Wintrobe’s Clinical Hematology. 10 Ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. p. 1367–1395.
  243. 243. González-Cueto D, Bruno S, Bustos-Fernández LM, Narbaitz M. Gastric solitary plasmacytoma associated withHelicobacter pyloriinfection. Acta Gastroenterol Latinoam. 1999; 29: 119–123.
  244. 244. Kato K, Sugitani M, Nagata T, Nishinarita S, Kawamura F, Takahashi Y, et al. A case of gastric plasmacytoma associated withHelicobacter pyloriinfection: improvement of abnormal endoscopic and EUS findings afterH. pylorieradication. Gastrointest Endosc. 2001; 53: 352–355.
  245. 245. Papadaki HA, Skordilis P, Minadakis G, Roussomoustakaki M, Katrinakis G, Psyllaki M, et al. Complete regression of primary gastric plasmacytoma followingHelicobacter pylorieradication. Ann Hematol. 2003; 82: 589–592.
  246. 246. Tursi A, Modeo ME. Monoclonal gammopathy of undetermined significance predisposing toHelicobacter pylori-related gastric mucosa-associated lymphoid tissue lymphoma. J Clin Gastroenterol. 2002; 34: 147–149.
  247. 247. Braggio E, Fonseca R. Genomic abnormalities of Waldenström macroglobulinemia and related low-grade B-cell lymphomas. Clin Lymphoma Myeloma Leuk. 2013; 13: 198–201. DOI: 10.1016/j.clml.2013.02.015.
  248. 248. Feingold ML, Goldstein MJ, Lieberman PH. Multiple myeloma involving the stomach. Report of a case with gastroscopic observations. Gastrointest Endosc. 1969; 16: 107–110.
  249. 249. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med. 1970; 283: 1121–1125.
  250. 250. Law IP, Blom J. Second malignancies in patients with multiple myeloma. Oncology 1977; 34: 20–24.
  251. 251. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979; 301: 743–748.
  252. 252. Nelson RS. Tumores malignos del estómago distintos del carcinoma. In: Berk JE, Haubrich WS, Kalser M, Roth JLA, Vilardell F, editors. Gastroenterología. Henry Bockus. 3th Ed. Barcelona, España: Salvat Editores, S.A. ; 1980. p. 1058–1078.
  253. 253. Brouet JC, Fermand JP, Laurent G, Grange MJ, Chevalier A, Jacquillat C, et al. The association of chronic lymphocytic leukaemia and multiple myeloma: a study of eleven patients. Br J Haematol. 1985; 59: 55–66.
  254. 254. Kaufmann H, Ackermann J, Nosslinger T, Kromer E, Zojer N, Schreiber S, et al. Absence of clonal chromosomal relationship between concomitant B-CLL and multiple myeloma––a report on two cases. Ann Hematol. 2001; 80: 474–478.
  255. 255. Wöhrer S, Isaacson PG, Raderer M. Complete regression of primary gastric plasmacytoma followingHelicobacter pylorieradication. Ann Hematol. 2004; 83: 666.
  256. 256. Wöhrer S, Raderer M, Streubel B, Chott A, Drach J. Concomitant occurrence of MALT lymphoma and multiple myeloma. Ann Hematol. 2004; 83: 600–603.
  257. 257. Malik AA, Ganti AK, Potti A, Levitt R, Hanley JF. Role ofHelicobacter pyloriinfection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. Am J Gastroenterol. 2002; 97: 1371–1374.
  258. 258. Wolkersdorfer GW, Haase M, Morgner A, Baretton G, Miehlke S. Monoclonal gammopathy of undetermined significance and russell body formation inHelicobacter pylorigastritis. Helicobacter 2006; 11: 506–510.
  259. 259. Rajkumar SV, Kyle RA, Plevak MF, Murray JA, Therneau TM.Helicobacter pyloriinfection and monoclonal gammopathy of undetermined significance. Br J Haematol. 2002; 119: 706–708.
  260. 260. Lehtinen M, Ogmundsdottir HM, Bloigu A, Hakulinen T, Hemminki E, Gudnadottir M, et al. Associations between three types of maternal bacterial infection and risk of leukemia in the offspring. Am J Epidemiol. 2005; 162: 662–667. DOI: 10.1093/aje/kwi261.
  261. 261. Diamantidis MD, Ioannidou-Papagiannaki E, Kountouras J, Mandala E, Tsapournas G, Frida-Michailidou I, et al. High prevalence ofHelicobacter pyloriinfection in Greek patients with myelodysplastic syndromes. Acta Haematol. 2010; 124: 141–149. DOI: 10.1159/000319629.
  262. 262. Kawamata T, Tojo A.Helicobacter pylori-induced thrombocytosis clinically indistinguishable from essential thrombocythemia. Leuk Lymphoma. 2012; 53: 1423–1424. DOI: 10.3109/10428194.2011.653787.
  263. 263. Fioredda F, Haupt R, Castagnola E, Barabino A, Micalizzi C, Dini G, et al.Helicobacter pylori-associated large gastric ulcer during treatment for childhood leukemia. J Pediatr Hematol Oncol. 2002; 24: 759–762.
  264. 264. Dolatkhah R, Khoshbaten M, Asvadi Kermani I, Reza Bonyadi M, Ghojazadeh M, Sanaat Z, et al. Upper gastrointestinal bleedings in patients with hereditary coagulation disorders in Northwest of Iran: prevalence ofHelicobacter pyloriinfection. Eur J Gastroenterol Hepatol. 2011; 23: 1172–1177. DOI: 10.1097/MEG.0b013e32834b0e7a.
  265. 265. Schulman S, Rehnberg AS, Hein M, Hegedus O, Lindmarker P, Hellstrom PM.Helicobacter pyloricauses gastrointestinal hemorrhage in patients with congenital bleeding disorders. Thromb Haemost. 2003; 89: 741–746.
  266. 266. Braden B, Wenke A, Karich HJ, Dietrich CF, Scharrer I, Caspary WF, et al. Risk of gastrointestinal bleeding associated with Helicobacter pylori infection in patients with hemophilia or von Willebrand's syndrome. Helicobacter 1998; 3: 184–187.
  267. 267. Tincani E, Bertoni G, Silingardi M, Ghirarduzzi A, Bedogni G, Iori I. Helicobacter pylori, a frequent and potentially dangerous guest in the gastroduodenal mucosa of anticoagulated patients. Am J Med. 2000; 108: 165–167.

Written By

Germán Campuzano-Maya

Submitted: May 21st, 2015 Reviewed: March 9th, 2016 Published: July 7th, 2016